The association between serum Lp(a) concentrations and coronary atherosclerosisDependence on serum LDL lev

Atherosclerosis

62, 249-257

DOI: 10.1016/0021-9150(86)90099-7

Citation Report

#	Article	IF	CITATIONS
1	Comparison of Lipoproteins between Chimpanzees and Humans., 1994,, 134-142.		0
2	Effect of cervical spinal cord lesions on early components of the median nerve somatosensory evoked potential. Neurology, 1986, 36, 20-20.	1.5	52
3	Structural Relationship of an Apolipoprotein (a) Phenotype (570 kDa) to Plasminogen: Homologous Kringle Domains are Linked by Carbohydrate-Rich Regions. Biological Chemistry Hoppe-Seyler, 1987, 368, 1533-1544.	1.4	125
4	Serum lipoprotein Lp(a) concentrations are not influenced by an HMG CoA reductase inhibitor. Klinische Wochenschrift, 1988, 66, 462-463.	0.6	112
5	The apolipoprotein(a) gene resides on human chromosome 6q26?27, in close proximity to the homologous gene for plasminogen. Human Genetics, 1988, 79, 352-6.	1.8	116
6	Genetics of the quantitative Lp(a) lipoprotein trait. Human Genetics, 1988, 78, 41-46.	1.8	194
7	Genetics of the quantitative Lp(a) lipoprotein trait. Human Genetics, 1988, 78, 47-50.	1.8	173
8	Influence of probucol administration on lipoprotein cholesterol and apolipoproteins in normolipemic males. Atherosclerosis, 1988, 72, 49-54.	0.4	12
9	Immunochemical characterization and quantitation of lipoprotein (a) in baboons. Atherosclerosis, 1988, 73, 23-31.	0.4	42
10	Apolipoprotein-B and Atherogenesis. Lancet, The, 1988, 331, 1141-1142.	6.3	1
11	APOLIPOPROTEINS (a), AI, AND B AND PARENTAL HISTORY IN MEN WITH EARLY ONSET ISCHAEMIC HEART DISEASE. Lancet, The, 1988, 331, 1070-1073.	6.3	254
12	FETAL HAEMOGLOBIN MEASUREMENT IN THE ASSESSMENT OF RED CELL ISOIMMUNISATION. Lancet, The, 1988, 331, 1073-1075.	6.3	219
13	LIPOPROTEIN(a), CHOLESTEROL, AND CORONARY HEART DISEASES. Lancet, The, 1988, 332, 963.	6.3	9
14	Penicillin-resistant Pneumococci. Lancet, The, 1988, 331, 1142-1143.	6.3	1
15	INCREASED LIPOPROTEIN(a) LEVELS IN CHILDREN WITH FAMILIAL HYPERCHOLESTEROLAEMIA. Lancet, The, 1988, 332, 1262-1263.	6.3	13
16	Lipoprotein(a): A Genetically Determined Lipoprotein Containing a Glycoprotein of the Plasminogen Family. Seminars in Thrombosis and Hemostasis, 1988, 14, 266-270.	1.5	16
17	Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients Circulation, 1988, 77, 1238-1244.	1.6	261
18	Biochemistry and Clinical Significance of Lipoprotein (a). Annals of Clinical Biochemistry, 1988, 25, 499-503.	0.8	15

#	Article	IF	CITATIONS
19	Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it EMBO Journal, 1989, 8, 4035-4040.	3 . 5	92
20	Apoprotein Measurements and Their Clinical Application. Clinics in Laboratory Medicine, 1989, 9, 137-152.	0.7	44
21	Plasma lipoprotein(a) and the Friedewald formula Clinical Chemistry, 1989, 35, 2156-2157.	1.5	4
22	HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels Circulation, 1989, 80, 1313-1319.	1.6	323
23	Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation Arteriosclerosis (Dallas, Tex), 1989, 9, 593-603.	4.9	252
24	The mysteries of lipoprotein(a). Science, 1989, 246, 904-910.	6.0	1,234
25	Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients Arteriosclerosis (Dallas, Tex), 1989, 9, 579-592.	4.9	443
26	Clinical significance of plasma lipid levels. American Journal of Cardiology, 1989, 64, G3-G9.	0.7	7
27	Effect of HELP‣DLâ€apheresis on serum concentrations of human lipoprotein(a): kinetic analysis of the postâ€treatment return to baseline levels. European Journal of Clinical Investigation, 1989, 19, 235-240.	1.7	108
28	The gene for the Lp(a)-specific glycoprotein is closely linked to the gene for plasminogen on chromosome 6. Human Genetics, 1989, 81, 149-152.	1.8	75
29	A potential basis for the thrombotic risks associated with lipoprotein(a). Nature, 1989, 339, 301-303.	13.7	573
30	Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature, 1989, 339, 303-305.	13.7	678
31	A rapid electrophoretic method for the detection of serum Lp(a) lipoprotein. Clinica Chimica Acta, 1989, 185, 147-155.	0.5	23
32	The Hyperlipoproteinemias. Medical Clinics of North America, 1989, 73, 859-893.	1.1	8
33	Defects in the low density lipoprotein receptor gene affect lipoprotein (a) levels: multiplicative interaction of two gene loci associated with premature atherosclerosis Proceedings of the National Academy of Sciences of the United States of America, 1989, 86, 4171-4174.	3.3	207
34	The Apo(a) gene: Structure/function relationships and the possible link with thrombotic atheromatous disease. British Medical Bulletin, 1990, 46, 873-890.	2.7	9
35	Interaction of lipoprotein(a) with fibronectin and its potential role in atherogenesis. European Heart Journal, 1990, 11, 190-195.	1.0	21
36	Serum Lp(a) lipoprotein concentrations of japanese patients with coronary heart disease Tohoku Journal of Experimental Medicine, 1990, 162, 261-267.	0.5	4

#	ARTICLE	IF	CITATIONS
37	A case of hyperLp(a) aemia, associated with systemic lupus erythematosus, suffering from myocardial infarction and cerebral infarction Japanese Journal of Medicine, 1990, 29, 77-84.	0.1	9
38	Morphological detection and quantification of lipoprotein(a) deposition in atheromatous lesions of human aorta and coronary arteries. Virchows Archiv A, Pathological Anatomy and Histopathology, 1990, 417, 105-111.	1.4	90
39	Variation in the size of human apolipoprotein(a) is due to a hypervariable region in the gene. Human Genetics, 1990, 84, 563-7.	1.8	42
40	Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clinical Chemistry, 1990, 36, 20-23.	1.5	399
41	The unique lipoprotein(a): properties and immunochemical measurement. Clinical Chemistry, 1990, 36, 2019-2026.	1.5	123
42	A monoclonal-antibody-based enzyme-linked immunosorbent assay of lipoprotein(a). Clinical Chemistry, 1990, 36, 192-197.	1.5	51
43	Immunological assays of apolipoproteins in plasma: methods and instrumentation. Clinical Chemistry, 1990, 36, 591-597.	1.5	84
44	Immunological evidence for the accumulation of lipoprotein(a) in the atherosclerotic lesion of the hypoascorbemic guinea pig Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 9388-9390.	3.3	40
45	Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men BMJ: British Medical Journal, 1990, 301, 1248-1251.	2.4	494
46	Hypothesis: lipoprotein(a) is a surrogate for ascorbate Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 6204-6207.	3.3	55
47	Relation of Serum Lipoprotein(a) Concentration and Apolipoprotein(a) Phenotype to Coronary Heart Disease in Patients with Familial Hypercholesterolemia. New England Journal of Medicine, 1990, 322, 1494-1499.	13.9	582
48	Research Initiatives in Vascular Surgery*. Journal of Vascular Surgery, 1990, 12, 194-217.	0.6	1
49	Endothelial cell fibrinolytic assembly. Journal of Vascular Surgery, 1990, 12, 210-211.	0.6	0
50	Influence of dietary fish oils on plasma Lp(a) levels. Thrombosis Research, 1990, 58, 667-668.	0.8	23
51	Factors influencing the accumulation in fibrous plaques of lipid derived from low density lipoprotein. Atherosclerosis, 1990, 84, 165-171.	0.4	67
52	Factors influencing the accumulation in fibrous plaques of lipid derived from low density lipoprotein. Atherosclerosis, 1990, 84, 173-181.	0.4	124
53	Lipoprotein (a): structure, properties and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis, 1990, 85, 1-14.	0.4	231
54	Does electrophoresis reliably screen for high serum lipoprotein Lp(a)?. Clinica Chimica Acta, 1990, 188, 71-77.	0.5	9

#	Article	IF	Citations
55	The increased plasma Lp(a): B lipoprotein particle concentration in angina pectoris is not associated with hypofibrinolysis. Clinica Chimica Acta, 1990, 188, 119-127.	0.5	33
56	Short- and long-term effects of LDL-apheresis on lipoprotein (a) serum levels. Clinica Chimica Acta, 1990, 195, 9-15.	0.5	23
57	Immunochemical determination of lipoprotein Lp(a): comparison of Laurell electrophoresis and ELISA. Clinica Chimica Acta, 1990, 188, 187-192.	0.5	21
58	Apolipoprotein E polymorphism affects plasma levels of lipoprotein(a). Atherosclerosis, 1991, 90, 169-174.	0.4	74
59	Dietary fish oil lowers lipoprotein(a) in primary hypertriglyceridemia. Atherosclerosis, 1991, 90, 95-97.	0.4	61
60	Vessel Wall-Related Risk Factors in Acute Vascular Events. Drugs, 1991, 42, 1-9.	4.9	14
61	Use of Niacin as a Drug. Annual Review of Nutrition, 1991, 11, 169-187.	4.3	100
62	Oxidation of lipoprotein Lp(a). A comparison with low-density lipoproteins. Lipids and Lipid Metabolism, 1991, 1081, 65-74.	2.6	128
63	Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor Pravastatin: results of a 2-year investigation. Clinica Chimica Acta, 1991, 204, 291-300.	0.5	42
64	The effect of n-3 polyunsaturated fatty acids on Lp(a). Clinica Chimica Acta, 1991, 198, 271-277.	0.5	38
65	Endothelial Cell Fibrinolytic Assembly. Annals of the New York Academy of Sciences, 1991, 614, 240-249.	1.8	24
66	Fibrinolytic parameters and lipoprotein (a) levels in plasma of patients with coronary artery disease. Thrombosis Research, 1991, 63, 407-418.	0.8	40
67	Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis, 1991, 89, 59-67.	0.4	337
68	Does lipoprotein(a) (Lp(a)) compete with plasminogen in human atherosclerotic lesions and thrombi?. Atherosclerosis, 1991, 89, 127-136.	0.4	37
69	Lipoprotein Lp(a) in homozygous familial hypercholesterolemia: density profile, particle heterogeneity and apolipoprotein(a) phenotype. Atherosclerosis, 1991, 86, 69-83.	0.4	30
70	Kinetic analysis of lipoprotein (a) inhibition of plasminogen activation by tissue plasminogen activator in vitro. Fibrinolysis, 1991, 5, 233-238.	0.5	20
71	Lipoprotein(a) and Atherosclerosis. Annals of Internal Medicine, 1991, 115, 209-218.	2.0	250
72	The Lipoprotein(A). Significance and Relation to Atherosclerosis. Acta Clinica Belgica, 1991, 46, 371-383.	0.5	1

#	ARTICLE	IF	Citations
73	A Comparison of Commercial Kits for the Measurement of Lipoprotein(a). Annals of Clinical Biochemistry, 1991, 28, 359-364.	0.8	25
74	Clinical Value of Apolipoprotein Measurement. Annals of Clinical Biochemistry, 1991, 28, 427-437.	0.8	21
75	A study of the clinical significance of lipoprotein (a) in nephrotic syndrome Japanese Journal of Medicine, 1991, 30, 21-25.	0.1	22
76	Abnormalities of cholesterol metabolism in diabetes. Proceedings of the Nutrition Society, 1991, 50, 583-589.	0.4	12
77	Characterization of the enzyme activity of human plasma lipoprotein (a) using synthetic peptide substrates. Biochemical Journal, 1991, 274, 491-496.	1.7	16
78	Interactions of lipoproteins with vascular intima in atherosclerosis. Biochemical Society Transactions, 1991, 19, 235-241.	1.6	7
79	Lipoprotein (a) blood levels in unstable angina pectoris, acute myocardial infarction, and after thrombolytic therapy. American Journal of Cardiology, 1991, 67, 1175-1179.	0.7	16
80	Elevation of factor VII activity and mass in coronary artery disease of varying severity. Clinical Cardiology, 1991, 14, 731-736.	0.7	47
81	Determination of Lp(a) and APO(a) in an Italian population. Research in Clinic and Laboratory, 1991, 21, 127-134.	0.3	2
82	Apolipoprotein (a) levels in type 1 and type 2 diabetes mellitus. Acta Diabetologica, 1991, 28, 158-161.	1.2	12
83	Lipoprotein (a) concentrations as risk indicators for atherosclerosis Archives of Disease in Childhood, 1991, 66, 1054-1056.	1.0	37
84	Abnormalities of Lipoprotein Metabolism in the Nephrotic Syndrome. New England Journal of Medicine, 1991, 324, 697-698.	13.9	13
85	Racial (black-white) differences in serum lipoprotein (a) distribution and its relation to parental myocardial infarction in children. Bogalusa Heart Study Circulation, 1991, 84, 160-167.	1.6	163
86	Lipoprotein(a) in diet-induced atherosclerosis in nonhuman primates Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1991, 11, 32-38.	3.8	41
87	Clinical signs of familial hypercholesterolemia in patients with familial defective apolipoprotein B-100 and normal low density lipoprotein receptor function Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1991, 11, 691-703.	3.8	78
88	Serum lipoprotein(a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1991, 11, 940-946.	3.8	89
89	Inverse Relationship Between Serum Lp(a) Levels and First-Phase Insulin Secretion. Diabetes, 1992, 41, 1341-1345.	0.3	23
90	Lipoproteins and their genetic variation in subjects with and without angiographically verified coronary artery disease Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1992, 12, 58-69.	3.8	78

#	Article	IF	Citations
91	Serum Lp(a) as a discriminant marker of early atherosclerotic plaque at three extracoronary sites in hypercholesterolemic men. The PCVMETRA Group Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1992, 12, 1346-1352.	3.8	69
92	Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients Circulation, 1992, 86, 475-482.	1.6	281
93	Significant association between low-molecular-weight apolipoprotein(a) isoforms and intermittent claudication Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1992, 12, 895-901.	3.8	72
94	Effect of Pravastation on Serum Lipids, Apolipoproteins and Lipoprotein (a) in Patients with Non-Insulin Dependent Diaabetes Mellitus Endocrinologia Japonica, 1992, 39, 45-50.	0.5	15
95	Lp(a) levels in patients undergoing aorto-coronary bypass surgery. European Heart Journal, 1992, 13, 1405-1409.	1.0	16
96	Serum Lipoprotein(a) Levels in Racially Different Populations. American Journal of Epidemiology, 1992, 136, 441-449.	1.6	67
97	Lipoprotein(a): A New Risk Factor for Vascular Disease. Perspectives in Vascular Surgery and Endovascular Therapy, 1992, 5, 84-99.	0.6	2
98	Characterization by yeast artificial chromosome cloning of the linked apolipoprotein(a) and plasminogen genes and identification of the apolipoprotein(a) 5' flanking region Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 11584-11588.	3.3	42
99	Lp(a) lipoprotein: Relationship to cardiovascular disease risk factors, exercise, and estrogen. American Journal of Obstetrics and Gynecology, 1992, 166, 1182-1190.	0.7	101
100	Studies on apolipoprotein(a) phenotypes. Part 1. Phenotype frequencies in a healthy Japanese population. Atherosclerosis, 1992, 96, 1-8.	0.4	41
101	Studies on apolipoprotein(a) phenotypes. Part 2. Phenotype frequencies and Lp(a) concentrations in different phenotypes in patients with angiographically defined coronary artery diseases. Atherosclerosis, 1992, 96, 9-15.	0.4	45
102	Increased serum apolipoprotein(a) in patients with chronic renal failure treated with continuous ambulatory peritoneal dialysis. Atherosclerosis, 1992, 93, 53-57.	0.4	31
103	Correlation of apolipoprotein(a) isoproteins with Lp(a) density and distribution in fasting plasma. Atherosclerosis, 1992, 94, 223-232.	0.4	36
104	On the role of coagulation and fibrinolysis in atherosclerosis. Annals of Epidemiology, 1992, 2, 427-438.	0.9	66
105	Euglobulin clot lysis induced by tissue-type plasminogen activator is reduced in subjects with increased levels of lipoprotein(a). Thrombosis Research, 1992, 66, 569-582.	0.8	19
106	Lipoprotein(a) levels in chronic renal disease states, dialysis and transplantation. Australian and New Zealand Journal of Medicine, 1992, 22, 243-248.	0.5	53
107	Lipoprotein(a): a new independent risk factor for atherosclerosis. Australian and New Zealand Journal of Medicine, 1992, 22, 326-328.	0.5	5
108	A cross-sectional evaluation of cardiovascular risk factors in coronary heart disease associated with Type 1 (insulin-dependent) diabetes mellitus. Diabetes Research and Clinical Practice, 1992, 18, 173-184.	1.1	30

#	Article	IF	CITATIONS
109	Lipoprotein(a) interactions to several fibrinolytic factors and their plasma level changes due to age in healthy, coronary heart disease and stroke subjects. Fibrinolysis, 1992, 6, 58-62.	0.5	0
110	Multiple members of the plasminogen-apolipoprotein(a) gene family associated with thrombosis. Biochemistry, 1992, 31, 3113-3118.	1.2	79
111	Treatment of hypothyroidism reduces low-density lipoproteins but not lipoprotein(a). Metabolism: Clinical and Experimental, 1992, 41, 911-914.	1.5	41
112	Isolation and characterization of two sub-species of Lp(a), one containing apo E and one free of apo E. Lipids and Lipid Metabolism, 1992, 1127, 124-130.	2.6	30
113	An indirect sandwich ELISA for LP(a) in serum and dried blood spots. Clinica Chimica Acta, 1992, 207, 73-86.	0.5	38
114	Treatment of Hyperlipidemic Kidney Graft Recipients with Lovastatin: Effect on LDL-Cholesterol and Lipoprotein (a). Nephron, 1992, 62, 394-398.	0.9	15
115	Measurement of low-density-lipoprotein cholesterol in serum: a status report. Clinical Chemistry, 1992, 38, 150-160.	1.5	141
116	Decreases in Apolipoprotein(a) after Renal Transplantation: Implications for Lipoprotein(a) Metabolism. Clinical Chemistry, 1992, 38, 353-357.	1.5	90
117	Plasma Lipoprotein(a) Values and Severity of Coronary Artery Disease in a Large Population of Patients Undergoing Coronary Angiography. Clinical Chemistry, 1992, 38, 2261-2266.	1.5	53
118	Effect of Lyophilization on Determinations of Lipoprotein(a) in Serum. Clinical Chemistry, 1992, 38, 1355-1360.	1.5	10
119	Does Serum Lipoprotein(a) Concentration Predict Restenosis After Percutaneous Transluminal Coronary Angioplasty?., 1992,, 211-216.		0
120	Dissociation-Enhanced Lanthanide Fluorescence Immunoassay of Lipoprotein(a) in Serum. Clinical Chemistry, 1992, 38, 853-859.	1.5	21
121	Review: Stratton Lecture. Thrombosis and atherogenesis: molecular connections. Blood, 1992, 79, 1897-1906.	0.6	86
122	Differences in apolipoprotein(a) polymorphism in West Greenland Eskimos and Caucasian Danes. Human Genetics, 1992, 89, 384-8.	1.8	28
123	Comparison of three methods of isolating lipoprotein (a) from human blood plasma. Bulletin of Experimental Biology and Medicine, 1992, 113, 345-348.	0.3	1
124	Cholesterol and lipoproteins: Beyond atherogenesis. Clinical Cardiology, 1992, 15, 883-890.	0.7	6
125	Normal lipoprotein(a) concentrations and apolipoprotein(a) isoforms in patients with insulin-dependent diabetes mellitus. European Journal of Clinical Investigation, 1992, 22, 538-541.	1.7	34
126	Immunoquantification of lipoprotein(a): Comparison of nephelometry with electroimmunodiffusion. Journal of Clinical Laboratory Analysis, 1993, 7, 256-262.	0.9	12

#	ARTICLE	IF	CITATIONS
127	Lipoprotein (a), low-density, intermediate-density lipoprotein, and blood pressure in a young male population. The Clinical Investigator, 1993, 71, 145-9.	0.6	11
128	High degree of genetic polymorphism in apolipoprotein(a) associated with plasma lipoprotein(a) levels in Japanese and Chinese populations. Human Genetics, 1993, 92, 537-544.	1.8	16
129	Frequent occurrence of familial aggregations of high lipoprotein(a) levels associated with small apolipoprotein(a) isoforms. Human Genetics, 1993, 92, 545-548.	1.8	4
130	Apolipoprotein(a) phenotypes and serum lipoprotein(a) levels in maintenance hemodialysis patients with/without diabetes mellitus. Kidney International, 1993, 44, 1062-1070.	2.6	51
131	Lipoprotein(a) in nephrotic syndrome. Kidney International, 1993, 44, 1116-1123.	2.6	57
132	Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by pravastatin in patients with familial hypercholesterolaemia treated with bile acid sequestration. European Journal of Clinical Investigation, 1993, 23, 240-245.	1.7	34
133	Acute myocardial infarction in a young man. Trends in Cardiovascular Medicine, 1993, 3, 44-47.	2.3	3
134	Relation of coronary artery disease in women <60 years of age to the combined elevation of serum lipoprotein (a) and total cholesterol to high-density cholesterol ratio. American Journal of Cardiology, 1993, 72, 1215-1219.	0.7	70
135	Lipoprotein (a): A Risk Factor for Peripheral Vascular Disease. Annals of Vascular Surgery, 1993, 7, 446-451.	0.4	40
136	Euglobulin clot lysis induced by tissue type plasminogen activator in subjects with increased levels and different isoforms of lipoprotein (a). Thrombosis Research, 1993, 72, 459-465.	0.8	19
137	Relationships between lipoprotein(a), lipids, apolipoproteins, basal and stimulated fibrinolytic regulators, and d-dimer. Metabolism: Clinical and Experimental, 1993, 42, 236-246.	1.5	88
138	Inheritance conjointly contributing to fibrinolysis and hyperlipidemia. Metabolism: Clinical and Experimental, 1993, 42, 1410-1419.	1.5	11
139	Determination of lipoprotein(a): enzyme immunoassay and immunoradiometric assay compared. Clinica Chimica Acta, 1993, 214, 153-163.	0.5	30
140	Lipoprotein(a): relation to other risk factors and genetic heritability. Results from a Dutch parent-twin study. Atherosclerosis, 1993, 99, 23-33.	0.4	76
141	Atherosclerosis at Volume 100: An appreciation. Atherosclerosis, 1993, 100, v-vi.	0.4	0
142	Reduction of lipoprotein(a) by LDL-apheresis using a dextran sulfate cellulose column in patients with familial hypercholesterolemia. Atherosclerosis, 1993, 100, 65-74.	0.4	38
143	The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover. Atherosclerosis, 1993, 101, 61-68.	0.4	91
144	Plasma triglycerides and lipoprotein(a): inverse relationship in a hyperlipidemic Italian population. Atherosclerosis, 1993, 101, 203-211.	0.4	54

#	Article	IF	Citations
145	Plasma Lp(a), apolipoprotein(a) isoforms and acute myocardial infarction in men and women: a case-control study in the Jerusalem population. Atherosclerosis, 1993, 98, 139-151.	0.4	49
146	Lp(a) levels and antiestrogen antibodies in women with and without thrombosis in the course of oral contraception. Atherosclerosis, 1993, 100, 183-188.	0.4	6
147	Niceritrol-induced reductions in serum lipoprotein(a) continue for one year. Current Therapeutic Research, 1993, 54, 550-552.	0.5	4
148	Serum lipoprotein(a) in healthy Japanese children 5 years of age. Pediatrics International, 1993, 35, 302-305.	0.2	8
149	Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients?. Lancet, The, 1993, 341, 268-270.	6.3	78
150	Elevated Lipoprotein (a) Levels in Primary Nephrotic Syndrome. American Journal of Kidney Diseases, 1993, 22, 808-813.	2.1	38
151	Lipoprotein(a) in Patients Treated by Continuous Ambulatory Peritoneal Dialysis. American Journal of Kidney Diseases, 1993, 22, 226-232.	2.1	29
152	On lipoprotein(a) and the coagulation/fibrinolysis balance in the acute phase of deep venous thrombosis. Fibrinolysis, 1993, 7, 83-86.	0.5	8
153	Lipoprotein[a] concentrations and apolipoprotein[a] phenotypes in Caucasians and African Americans. The CARDIA study Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993, 13, 1037-1045.	3.8	113
154	The relation of lipoprotein[a] concentrations and apolipoprotein[a] phenotypes with asymptomatic atherosclerosis in subjects of the Atherosclerosis Risk in Communities (ARIC) Study Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993, 13, 1558-1566.	3.8	67
155	Lipoprotein(a) and apolipoprotein B plasma concentrations in hypothyroid, euthyroid, and hyperthyroid subjects Journal of Clinical Endocrinology and Metabolism, 1993, 76, 121-126.	1.8	84
156	Apolipoprotein (a) concentrations and susceptibility to coronary artery disease in patients with peripheral vascular disease Heart, 1993, 69, 26-30.	1.2	9
157	Lipoprotein(a) Serum Levels and Apolipoprotein(a) Phenotypes in Children with Chronic Renal Disease. Pediatric Research, 1993, 34, 772-776.	1.1	57
158	Determination of Lipoprotein(a): Evaluation of Three Methods. Clinical Chemistry and Laboratory Medicine, 1993, 31, 295-302.	1.4	8
159	Lipoprotein[a] as a risk factor for preclinical atherosclerosis Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993, 13, 826-833.	3.8	117
160	Interaction of Lp(a) and of apo(a) with liver cells Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993, 13, 1101-1109.	3.8	33
161	Lipoprotein (a) as an independent risk factor for myocardial infarction in patients with common hypercholesterolaemia Journal of Clinical Pathology, 1993, 46, 267-270.	1.0	11
162	Serum Lipoprotein(a) in Patients With Diabetes Mellitus. Diabetes Care, 1993, 16, 819-823.	4.3	64

#	ARTICLE	IF	CITATIONS
163	Effects of age, sex, and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study Circulation, 1993, 87, 1135-1141.	1.6	306
164	Pre-Analytical, Analytical and Biological Sources of Variation of Lipoprotein(a). Clinical Chemistry and Laboratory Medicine, 1993, 31, 23-8.	1.4	3
165	The relationship between serum lipoprotein (a) and Restenosis after initial elective percutaneous transluminal coronary angioplasty Japanese Circulation Journal, 1993, 57, 789-795.	1.0	29
166	Plasma lipoprotein(a) levels and fibrinolytic activity in patients with unstable angina Japanese Circulation Journal, 1993, 57, 947-954.	1.0	2
167	Improved Blood Glucose Control by Insulin Therapy in Type 2 Diabetic Patients Has No Effect on Lipoprotein(a) Levels. Diabetic Medicine, 1993, 10, 427-430.	1.2	23
169	The Effect of Microalbuminuria on Glycaemic Control, Serum Lipids and Haemostasis Parameters in Non-Insulin-Dependent Diabetes Mellitus. Annals of Clinical Biochemistry, 1993, 30, 439-444.	0.8	11
170	One-step competitive immunochromatographic assay for semiquantitative determination of lipoprotein(a) in plasma. Clinical Chemistry, 1993, 39, 619-624.	1.5	82
171	Association between impaired glucose tolerance and circulating concentration of Lp(a) lipoprotein in relation to coronary heart disease BMJ: British Medical Journal, 1993, 307, 832-836.	2.4	7
172	Relation of lipoprotein(a) in 11- to 19-year-old adolescents to parental cardiovascular heart disease. Clinical Chemistry, 1993, 39, 477-480.	1.5	26
173	Quantification of lipoprotein(a) particles containing various apolipoprotein(a) isoforms by a monoclonal anti-apo(a) capture antibody and a polyclonal anti-apolipoprotein B detection antibody sandwich enzyme immunoassay. Clinical Chemistry, 1993, 39, 1382-1389.	1.5	50
175	Comparative analysis of the apo(a) gene, apo(a) glycoprotein, and plasma concentrations of Lp(a) in three ethnic groups. Evidence for no common "null" allele at the apo(a) locus Journal of Clinical Investigation, 1994, 93, 2526-2534.	3.9	114
176	Lipoprotein(A): Physiologic Function, Association with Atherosclerosis, and Effects of Lipid-Lowering Drug Therapy. Annals of Pharmacotherapy, 1994, 28, 343-351.	0.9	22
177	Comparison of Serum Lipoprotein(a) Distribution and its Correlates among Black and White Populations. International Journal of Epidemiology, 1994, 23, 20-27.	0.9	31
178	Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994, 14, 1399-1404.	3.8	81
179	Coronary artery disease is associated with increased lipoprotein(a) concentrations independent of the size of circulating apolipoprotein(a) isoforms Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994, 14, 1272-1283.	3.8	43
180	Plasma Lp(a) levels correlate with number, severity, and length-extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994, 14, 1730-1736.	3.8	95
181	Elevated serum insulin levels in patients with essential hypertension and microalbuminuria Hypertension, 1994, 23, 681-687.	1.3	96
182	Lipoprotein(a) in restenosis after percutaneous transluminal coronary angioplasty and coronary artery disease Circulation, 1994, 89, 1593-1598.	1.6	51

#	Article	IF	CITATIONS
183	Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994, 14, 1405-1411.	3.8	92
184	Association of apolipoprotein(a) phenotypes in children with family history of premature coronary artery disease Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994, 14, 1609-1616.	3.8	28
185	Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994, 14, 438-442.	3.8	83
186	Lipid Parameters Including Lp(a) in Hemodialysis Patients. Renal Failure, 1994, 16, 501-509.	0.8	12
187	Lp(a) Lipoprotein Is an Independent, Discriminating Risk Factor for Premature Peripheral Atherosclerosis Among White Men. Archives of Internal Medicine, 1994, 154, 801.	4.3	87
188	Binding of recombinant apolipoprotein(a) to extracellular matrix proteins Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994, 14, 1792-1798.	3.8	41
189	Serum Lp(a) lipoprotein concentration and outcome of thrombolytic treatment for myocardial infarction Heart, 1994, 71, 316-321.	1.2	20
190	A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study Circulation, 1994, 90, 1688-1695.	1.6	230
191	Lipids, Apolipoproteins and Lipoproteins. Developments in Cardiovascular Medicine, 1994, , 83-103.	0.1	10
192	Correlation Between Plasma Lipoprotein Lp(a)and Sex Hormone Concentrations: A Cross-Sectional Study in Healthy Males. Hormone and Metabolic Research, 1994, 26, 602-608.	0.7	11
193	Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS). European Journal of Clinical Investigation, 1994, 24, 444-453.	1.7	269
194	Proteolytic degradation of low-density lipoprotein by lipoprotein(a) and by recombinant apo(a). Chemistry and Physics of Lipids, 1994, 67-68, 25-33.	1.5	3
195	Effect of lipoprotein(a) on lipid metabolism of cultured human intimal aortic cells. Chemistry and Physics of Lipids, 1994, 67-68, 161-166.	1.5	4
196	Heparin extracorporeal LDL precipitation (HELP): an effective apheresis procedure for lowering Lp(a) levels. Chemistry and Physics of Lipids, 1994, 67-68, 315-321.	1.5	20
197	Structure and Possible biological roles of Lp(a). Clinical Biochemistry, 1994, 27, 151-162.	0.8	11
198	Lipoprotein(a): new insights into an atherogenic lipoprotein. The Clinical Investigator, 1994, 72, 558-67.	0.6	25
199	Hypervariable polymorphism of APO(a) in blacks and whites as reflected by phenotyping. Chemistry and Physics of Lipids, 1994, 67-68, 283-292.	1.5	12
200	The relationship between infant and parent Lp(a) levels. Chemistry and Physics of Lipids, 1994, 67-68, 299-304.	1.5	13

#	ARTICLE	IF	CITATIONS
201	Extracorporeal immunoadsorption for the specific removal of lipoprotein (a) (Lp(a) apheresis): preliminary clinical data. Chemistry and Physics of Lipids, 1994, 67-68, 323-330.	1.5	35
202	Lipoprotein(a) and coronary heart disease. Chemistry and Physics of Lipids, 1994, 67-68, 389-398.	1.5	17
203	Discrepancies between lipoprotein(a) concentrations in icteric sera measured by immunonephelometry and electroimmunodiffusion. Clinical Biochemistry, 1994, 27, 7-11.	0.8	4
204	Dyslipidemia and coronary artery disease. Clinical Cardiology, 1994, 17, 519-527.	0.7	12
205	Evidence that apolipoprotein(a) phenoptype is a risk factor for coronary artery disease in men < 55 years of age. American Journal of Cardiology, 1994, 74, 346-351.	0.7	30
206	Association between lipoprotein(a) and progression of coronary artery disease in middle-aged men. American Journal of Cardiology, 1994, 73, 742-746.	0.7	36
207	Effects of erythropoietin therapy on the lipid profile in end-stage renal failure. Kidney International, 1994, 45, 897-902.	2.6	40
208	The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients. Clinical Endocrinology, 1994, 41, 345-350.	1.2	140
209	Characterization of monoclonal antibodies to apolipoprotein (a) and development of a chemiluminescent assay for phenotyping apolipoprotein (a) isomorphs. Journal of Immunological Methods, 1994, 172, 43-58.	0.6	7
210	Apo(a) Expression in Transgenic Micea. Annals of the New York Academy of Sciences, 1994, 714, 231-236.	1.8	0
211	Lipids and Lp(a) Lipoprotein Levels and Coronary Artery Disease in Subjects With Non-Insulin-Dependent Diabetes Mellitus. Mayo Clinic Proceedings, 1994, 69, 430-435.	1.4	27
212	Low-density lipoprotein activates the protease region of recombinant apo(a). Lipids and Lipid Metabolism, 1994, 1215, 170-175.	2.6	4
213	Effect of storage of sera and apolipoprotein(a) phenotypes on detection of lipoprotein(a) by a new agarose gel. Clinica Chimica Acta, 1994, 225, 195-201.	0.5	3
214	Lipoprotein(a) concentration in various hyperlipidemias. Clinica Chimica Acta, 1994, 226, 105-107.	0.5	4
215	Relationship between lipoprotein(a) levels in serum and some indices of protein synthesis in liver cirrhosis. Clinica Chimica Acta, 1994, 224, 125-129.	0.5	14
216	The relationship between impaired fibrinolysis and coronary heart disease: a role for PAI-1. Fibrinolysis, 1994, 8, 294-303.	0.5	45
217	Relationship between angiographically assessed coronary artery disease, plasma insulin levels and lipids in Asians and Caucasians. Atherosclerosis, 1994, 105, 35-41.	0.4	13
218	Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis, 1994, 106, 9-19.	0.4	494

#	Article	IF	CITATIONS
219	Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis, 1994, 108, 111-126.	0.4	205
220	Decreased plasma levels of lipoprotein(a) in patients with hypertriglyceridemia. Atherosclerosis, 1994, 108, 149-157.	0.4	45
221	Effects of niceritrol on elevated serum lipoprotein Lp(a) levels in diabetic patients with or without overt proteinuria. Current Therapeutic Research, 1994, 55, 546-551.	0.5	1
222	Effects of doxazosin on blood pressure and serum lipid levels in hypertensive patients. Current Therapeutic Research, 1994, 55, 843-850.	0.5	O
223	Oat bran lowers total and low-density lipoprotein cholesterol but not lipoprotein(a) in exercising adults with borderline hypercholesterolemia. Journal of the American Dietetic Association, 1994, 94, 1419-1421.	1.3	9
224	Analysis of Angiographic Trial Data in Women. Drugs, 1994, 47, 11-15.	4.9	3
225	Haemostatic factors and prevalent coronary heart disease; the FINRISK haemostasis study. European Heart Journal, 1994, 15, 1293-1299.	1.0	44
226	Plasma lipoprotein (a) levels and fibrinolytic activity in acute myocardial infarction Japanese Circulation Journal, 1994, 58, 869-876.	1.0	7
227	Quantitation of Plasma Apolipoproteins in the Primary and Secondary Prevention of Coronary Artery Disease. Annals of Internal Medicine, 1994, 120, 1012.	2.0	187
229	Epidemiology of triglycerides, small dense low-density lipoprotein, and lipoprotein(a) as risk factors for coronary heart disease. Medical Clinics of North America, 1994, 78, 99-115.	1.1	63
230	The apolipoprotein B3304–3317 peptide as an inhibitor of the lipoprotein (a):apolipoprotein B-containing lipoprotein interaction. Biochemical Journal, 1995, 307, 17-22.	1.7	14
231	The binding of animal low-density lipoproteins to human apolipoprotein(a). Biochemical Journal, 1995, 309, 899-904.	1.7	16
232	Lipoprotein (a) does not influence hyperfibrinolysis in patients with liver cirrhosis. Fibrinolysis, 1995, 9, 133-138.	0.5	5
233	Comparison of effects of N-3 to N-6 fatty acids on serum level of lipoprotein(a) in patients with coronary artery disease. American Journal of Cardiology, 1995, 76, 459-462.	0.7	46
234	Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS) Tj ETQq0 0	0 rgBT /O	verlock 10 Tf
235	Lipoprotein (a) in patients with hyperlipidaemia. European Journal of Clinical Investigation, 1995, 25, 647-653.	1.7	14
236	Measurement of Lp(a) with a two-step monoclonal competitive sandwich ELISA method. Clinical Biochemistry, 1995, 28, 269-275.	0.8	3
237	Behavior of Lp(a) and apoproteins (A1, B, C2, C3, E) during and after therapy with simvastatin. Cardiovascular Drugs and Therapy, 1995, 9, 785-789.	1.3	12

#	Article	IF	CITATIONS
238	Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with hyperthyroidism. Journal of Molecular Medicine, 1995, 73, 41-46.	1.7	9
239	Sequence polymorphism in kringle IV 37 in linkage disequilibrium with the apolipoprotein (a) size polymorphism. Human Genetics, 1995, 95, 275-82.	1.8	41
240	Serum lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in the families of NIDDM patients. Diabetologia, 1995, 38, 1434-1442.	2.9	12
241	Involvement of Lipoprotein(a) in calcification of coronary arteries and thoracic aorta as detected by X-ray computed tomography. International Journal of Angiology, 1995, 4, 218-223.	0.2	5
242	Malignant coronary artery disease in young asian indians: Thoughts on pathogenesis, prevention, and therapy. Clinical Cardiology, 1995, 18, 131-135.	0.7	146
243	Serum concentrations of apolipoprotein A-I, apolipoprotein B, and lipoprotein(a) in a population sample. Clinical Chemistry, 1995, 41, 1633-1636.	1.5	47
244	Accumulation of atherogenic remnants and lipoprotein(a) in the nephrotic syndrome: relation to remission of proteinuria. Clinical Chemistry, 1995, 41, 908-913.	1.5	36
245	Direct determination of lipoprotein(a) cholesterol by ultracentrifugation and agarose gel electrophoresis with enzymatic staining for cholesterol. Clinical Chemistry, 1995, 41, 731-738.	1.5	34
246	Inhibitors for the In Vitro Assembly of Lp(a). Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 1774-1780.	1.1	41
247	Lipid Parameters Including Lipoprotein (A) in Patients Undergoing CAPD and Hemodialysis. Peritoneal Dialysis International, 1995, 15, 342-347.	1.1	60
248	Elevated Plasma Lipoprotein(a) Levels and Hypoalbuminemia in Peritoneal Dialysis Patients. International Journal of Artificial Organs, 1995, 18, 751-756.	0.7	7
249	Interrelationships between Lipoprotein(a) and Other Cardiovascular Risk Factors. Cardiology, 1995, 86, 432-435.	0.6	5
250	The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans Journal of Clinical Investigation, 1995, 95, 1403-1408.	3.9	177
252	Serum lipoprotein(a) concentrations are related to coronary disease progression without new myocardial infarction Heart, 1995, 74, 365-369.	1.2	18
253	A Two-step Model for Lipoprotein(a) Formation. Journal of Biological Chemistry, 1995, 270, 15471-15474.	1.6	69
254	Serum Lp(a) lipoprotein levels in patients with coronary artery disease and the influence of long-term n-3 fatty acid supplementation. Scandinavian Journal of Clinical and Laboratory Investigation, 1995, 55, 295-300.	0.6	29
255	Pubertal Serum Lipoprotein (a) and its Correlates in Belgian Schoolchildren. International Journal of Epidemiology, 1995, 24, 78-87.	0.9	17
256	ldentification of Two Functionally Distinct Lysine-binding Sites in Kringle 37 and in Kringles 32â°'36 of Human Apolipoprotein(a). Journal of Biological Chemistry, 1995, 270, 6227-6234.	1.6	86

#	Article	IF	CITATIONS
257	Effects of Lowering Elevated LDL Cholesterol on the Cardiovascular Risk of Lipoprotein(a). JAMA - Journal of the American Medical Association, 1995, 274, 1771.	3.8	220
258	Sequence microheterogeneity in apolipoprotein(a) gene repeats and the relationship to plasma Lp(a) levels. Human Molecular Genetics, 1995, 4, 1535-1542.	1.4	38
259	Time-Resolved Immunofluorometric Assay for the Quantification of Lipoprotein(a) in Serum. Clinical Chemistry and Laboratory Medicine, 1995, 33, 805-12.	1.4	0
260	Lipoprotein (a): A Prothrombotic Risk Factor for Coronary Artery Disease. European Journal of Cardiovascular Prevention and Rehabilitation, 1995, 2, 206-215.	3.1	6
261	Performance of a Direct, Immunoseparation Based LDL-Cholesterol Method Compared to Friedewald Calculation and a Polyvinyl Sulphate Precipitation Method. Clinical Chemistry and Laboratory Medicine, 1995, 33, 417-24.	1.4	3
262	Lipids and atherosclerosis. Molecular Aspects of Medicine, 1995, 16, 509-710.	2.7	10
263	Triiodothyronine rapidly lowers plasma lipoprotein (a) in hypothyroid subjects. Netherlands Journal of Medicine, 1995, 46, 179-184.	0.6	20
264	The effect of percutaneous oestrogen replacement therapy on Lp(a) and other lipoproteins. Maturitas, 1995, 22, 219-225.	1.0	15
265	Serum lipoprotein(a) levels before and after subtotal thyroidectomy in subjects with hyperthyroidism. Metabolism: Clinical and Experimental, 1995, 44, 4-7.	1.5	11
266	Association of lipoprotein(a) with atherothrombotic events and fibrinolytic variables. A case-control study. Thrombosis Research, 1995, 78, 227-238.	0.8	18
267	The effect of reduction of lipoprotein (a) on cellular cholesterol synthesis in non-diabetic and Type 2 diabetic subjects. Lipids and Lipid Metabolism, 1995, 1254, 187-192.	2.6	2
268	A sandwich ELISA based on anti-apo(a) and anti-apo B monoclonal antibodies for lipoprotein(a) measurement. Clinica Chimica Acta, 1995, 236, 59-70.	0.5	10
269	Whether, to what degree, and why lipoprotein(a) levels change over time. Clinica Chimica Acta, 1995, 238, 11-19.	0.5	13
270	Characterization of commercial antibodies for use in high resolution apo(a) phenotyping by immunoblot analysis. Clinica Chimica Acta, 1995, 240, 75-81.	0.5	5
271	Effect of gemfibrozil versus lovastatin on increased serum lipoprotein(a) levels of patients with hypercholesterolemia. International Journal of Cardiology, 1995, 48, 115-120.	0.8	23
272	Lipoprotein(a) plasma levels and apo(a) isoforms are not associated with longevity or disability in a sample of Italian octo- nonagenarians. Aging Clinical and Experimental Research, 1995, 7, 385-391.	1.4	14
273	Prevention of Complications in Non-Insulin-Dependent Diabetes Mellitus (NIDDM). Drugs, 1995, 50, 263-288.	4.9	39
274	Alterations of serum lipid levels and their biological relevances during and after pregnancy. Life Sciences, 1995, 56, 2367-2375.	2.0	134

#	Article	IF	CITATIONS
275	High levels of serum lipoprotein(a) in patients with ischemic heart disease with normal coronary angiogram and thromboangiitis obliterans. Atherosclerosis, 1995, 112, 253-260.	0.4	10
276	Extraction of lipoprotein(a), apo B, and apo E from fresh human arterial wall and atherosclerotic plaques. Atherosclerosis, 1995, 113, 179-188.	0.4	39
277	Thyroid hormone (fT4) reduces lipoprotein(a) plasma levels. Atherosclerosis, 1995, 115, 65-71.	0.4	17
278	Effect of immunosuppressive drug regime on cardiovascular risk profile following kidney transplantation. Atherosclerosis, 1995, 116, 241-245.	0.4	14
279	Genetic effect of apolipoprotein(a) and apolipoprotein E polymorphisms on plasma quantitative risk factors for coronary heart disease in American Black women. Atherosclerosis, 1995, 117, 73-81.	0.4	26
280	Coronary atherosclerosis stabilization: an achievable goal. Atherosclerosis, 1995, 118, S91-S101.	0.4	12
281	Familial Hypercholesterolaemia Regression Study and its implications. Lancet, The, 1995, 345, 807-808.	6.3	4
282	Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. Lancet, The, 1995, 345, 811-816.	6.3	232
283	Lipoprotein (a) and apolipoprotein $A\hat{a} \in \mathbb{I}$ and B in schoolchildren whose grandparents had coronary and cerebrovascular events: A preliminary study of $12\hat{a} \in \mathbb{I}$ year old Japanese children. Pediatrics International, 1995, 37, 582-587.	0.2	11
284	Lipoprotein (a). Bailliere's Clinical Endocrinology and Metabolism, 1995, 9, 773-795.	1.0	20
285	Thrombolysis with tissue plasminogen activator enhances serum lipoprotein(a) levels compared to streptokinase and conservative treatment in patients with acute myocardial infarction. Fibrinolysis, 1996, 10, 263-268.	0.5	3
286	Association of lipoprotein cholesterol and triglycerides with the severity of coronary artery disease in men and women. Atherosclerosis, 1996, 127, 213-220.	0.4	48
287	High serum concentration of lipoprotein(a) is a risk factor for restenosis after percutaneous transluminal coronary angioplasty in Japanese patients with single-vessel disease. American Heart Journal, 1996, 132, 269-273.	1.2	28
288	H.E.L.P. Apheresis Therapy in the Treatment of Severe Hypercholesterolemia: 10 Years of Clinical Experience. Artificial Organs, 1996, 20, 303-310.	1.0	28
289	Treatment of Severe Hyperlipidemia: Six Years' Experience with Low–Density Lipoprotein Apheresis. Artificial Organs, 1996, 20, 336-339.	1.0	5
290	Plasma lipoprotein(a) distribution in the Framingham Offspring Study as determined with a commercially available immunoturbidimetric assay. Clinica Chimica Acta, 1996, 253, 21-35.	0.5	26
291	Lipoprotein(a) in Health and Disease. Critical Reviews in Clinical Laboratory Sciences, 1996, 33, 495-543.	2.7	78
292	Hypercoagulability and high lipoprotein(a) levels in patients with type II diabetes mellitus. Atherosclerosis, 1996, 120, 7-14.	0.4	68

#	Article	IF	CITATIONS
293	PAF-acetylhydrolase activity on Lp(a) before and during Cu2+-induced oxidative modification in vitro. Atherosclerosis, 1996, 125, 121-134.	0.4	46
294	The influence of hypoalbuminemia in the generation of nephrotic hyperlipidemia. Atherosclerosis, 1996, 126, 243-252.	0.4	19
295	Lipoprotein(a) in renal disease. American Journal of Kidney Diseases, 1996, 27, 1-25.	2.1	227
296	Correlation of lipoprotein (a) to angiographically defined coronary artery disease in Indians. International Journal of Cardiology, 1996, 57, 265-270.	0.8	42
297	Lipoprotein(a) and its correlates in Japanese and U.S. population samples. Annals of Epidemiology, 1996, 6, 324-330.	0.9	8
298	Race and Gender Differences in the Association of Lp(a) With Carotid Artery Wall Thickness. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 471-478.	1.1	93
299	Lipoprotein(a) Inhibits Collagen-Induced Aggregation of Thrombocytes. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 648-655.	1.1	29
300	Plasma Lipoprotein(a) Levels in Subjects Attending a Metabolic Ward. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 120-128.	1.1	30
301	Impact of Nutritional Status on Serum Lipoprotein (A) Concentration in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis. Peritoneal Dialysis International, 1996, 16, 241-245.	1.1	10
302	Analysis of Apolipoproteins. Annals of Clinical Biochemistry, 1996, 33, 5-22.	0.8	8
303	[1] Apolipoproteins: Pathophysiology and clinical implications. Methods in Enzymology, 1996, 263, 3-32.	0.4	12
304	Lipoprotein(a) and Vascular Access Survival in Patients on Chronic Hemodialysis. Nephron, 1996, 72, 145-149.	0.9	16
305	Effect of sample storage on quantitation of lipoprotein (a) by an enzyme-linked immunosorbent assay. Lipids, 1996, 31, 1197-1203.	0.7	18
306	Lipid profile, haemostatic variables and angiographically-defined coronary artery disease: A cross-sectional study in an Irish population. Irish Journal of Medical Science, 1996, 165, 129-132.	0.8	1
307	Serum lipoprotein(a) levels in adolescents and young adults with insulin-dependent diabetes mellitus. European Journal of Pediatrics, 1996, 155, 995-996.	1.3	1
309	Factors influencing plasma lipid profiles including lipoprotein (a) concentrations in renal transplant recipients. Transplant International, 1996, 9, 221-226.	0.8	9
310	Lipid disorders contributing to coronary heart disease: An update. Current Problems in Cardiology, 1996, 21, 733-780.	1.1	5
311	Correlation of toddlers' serum lipoprotein(a) concentration with parental values and grandparents' coronary heart disease: the STRIP baby study. Acta Paediatrica, International Journal of Paediatrics, 1996, 85, 407-412.	0.7	17

#	Article	IF	CITATIONS
312	The association of serum lipoprotein(a) levels with myocardial infarction and ictus cerebri in the elderly. Archives of Gerontology and Geriatrics, 1996, 22, 213-216.	1.4	2
313	The assembly of lipoprotein Lp(a). European Journal of Clinical Investigation, 1996, 26, 109-114.	1.7	35
314	Decrease in lipoprotein(a) after renal transplantation is related to the glucocorticoid dose. European Journal of Clinical Investigation, 1996, 26, 668-675.	1.7	11
315	Serum Lipoprotein(a) Levels in a Greek Population Sample Without a History of Premature Myocardial Infarction. European Journal of Cardiovascular Prevention and Rehabilitation, 1996, 3, 277-279.	3.1	4
316	Thrombotic vascular risk factors in inflammatory bowel disease Gut, 1996, 38, 733-737.	6.1	114
317	THE ROLE OF LIPOPROTEIN(a) IN ATHEROGENESIS AND THROMBOSIS. Annual Review of Medicine, 1996, 47, 423-442.	5.0	88
318	Quantification of Lipoprotein(a): Comparison of an Automated Latex-Enhanced Nephelometric Assay with an Immunoenzymometric Method. Clinical Chemistry and Laboratory Medicine, 1996, 34, 119-24.	1.4	1
320	Treatment of prostate cancer with gonadotropin-releasing hormone analogue: effect on lipoprotein[a] Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2508-2511.	1.8	13
321	Tissue plasminogen activator, tissue plasminogen activator inhibitor and lipoprotein(a) in patients with coronary, eplaortic and peripheral occlusive artery disease. European Heart Journal, 1996, 17, 1329-1336.	1.0	14
322	Lipoprotein (a) distribution in a Nigerian population. Ethnicity and Health, 1997, 2, 47-58.	1.5	7
323	The effect of recombinant human GH replacement therapy on lipoprotein(a) and other lipid parameters in adults with acquired GH deficiency: results of a double-blind and placebo-controlled trial. European Journal of Endocrinology, 1997, 137, 459-466.	1.9	34
324	The role of apo-(a) kringle-IVs in the assembly of lipoprotein-(a). Protein Engineering, Design and Selection, 1997, 10, 291-298.	1.0	22
325	Serum Lp(a) lipoprotein concentration is not associated with clinical and angiographic outcome five years after coronary artery bypass graft surgery Heart, 1997, 78, 131-135.	1.2	18
326	Estrogen and Progestin Compared with Simvastatin for Hypercholesterolemia in Postmenopausal Women. New England Journal of Medicine, 1997, 337, 595-601.	13.9	189
327	Lipoprotein(a) in Korean Children and a History of Coronary or Cerebral Vascular Events in Their Older Family Members. Annals of Clinical Biochemistry, 1997, 34, 179-184.	0.8	6
328	Early Elevation of Lipoprotein(a) Levels in Chronic Renal Insufficiency. Renal Failure, 1997, 19, 145-154.	0.8	15
329	Elevated Serum Lipoprotein (a) Levels Associated with Ulcerative Colitis in a Young Japanese Patient Internal Medicine, 1997, 36, 389-391.	0.3	1
330	Urinary apo(a) discriminates coronary artery disease patients from controls. Atherosclerosis, 1997, 129, 103-110.	0.4	19

#	Article	IF	Citations
331	Apolipoprotein(a) isoforms and coronary heart disease in men. Atherosclerosis, 1997, 132, 77-84.	0.4	69
332	Effects of Visceral Fat and Weight Loss on Lipoprotein(a) Concentration in Subjects with Obesity. Obesity, 1997, 5, 332-337.	4.0	10
333	LIPOPROTEIN(a) CONCENTRATION AND MOLECULAR WEIGHT OF APOLIPOPROTEIN(a) IN PATIENTS WITH CEREBROVASCULAR DISEASE AND DIABETES MELLITUS. Thrombosis Research, 1997, 87, 527-538.	0.8	9
334	A simple visual immunoassay (VIA) for rapid identification of high lipoprotein(a) blood levels. Clinica Chimica Acta, 1997, 260, 65-71.	0.5	8
335	Lipoprotein (a) phenotype distribution in a population of bypass patients and its influence on lipoprotein (a) concentration. Clinica Chimica Acta, 1997, 265, 99-111.	0.5	4
336	Evaluation of a new automated latex agglutination assay for lipoprotein(a): comparison with a manual ELISA. Clinica Chimica Acta, 1997, 261, 175-183.	0.5	15
337	Lipoprotein (a) serum levels in patients with hepatocarcinoma. Clinica Chimica Acta, 1997, 262, 53-60.	0.5	17
338	The cardiovascular safety of triphasic contraceptive steroids. Contraception, 1997, 56, 157-163.	0.8	2
339	Lipoprotein(a) Selectively Impairs Receptor-Mediated Endothelial Vasodilator Function of the Human Coronary Circulation. Journal of the American College of Cardiology, 1997, 30, 927-934.	1.2	82
340	Middle-Aged Men With Symptomatic Coronary Artery Disease and Normal to Moderately Elevated Serum Cholesterol fn1fn1This study was supported by Bristol-Myers Squibb Co., Princeton, New Jersey (REGRESS main study) and by Grant 94.032 from the Dutch Heart Foundation, Den Haag, The Netherlands [lipoprotein(a) substudy] Journal of the American College of Cardiology, 1997, 30.	1.2	57
341	Lipoprotein(a) Interactions With Lipid and Nonlipid Risk Factors in Early Familial Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 2783-2792.	1.1	78
342	Combination of Low-Dose Niacin and Pravastatin Improves the Lipid Profile in Diabetic Patients without Compromising Glycemic Control. Annals of Pharmacotherapy, 1997, 31, 677-682.	0.9	25
343	Plasma Lipoprotein (a) Levels in Men and Women Consuming Diets Enriched in Saturated, <i>Cis</i> , or <i>Trans</i> -Monounsaturated Fatty Acids. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 1657-1661.	1.1	85
344	Six-Month Prospective Cross-Over Study to Determine the Effects of 1.1% Amino Acid Dialysate on Lipid Metabolism in Patients on Continuous Ambulatory Peritoneal Dialysis. Peritoneal Dialysis International, 1997, 17, 279-286.	1.1	33
345	Correlation between serum lipoprotein (a) and angiographic coronary artery disease in nonâ€insulinâ€dependent diabetes mellitus. Journal of Internal Medicine, 1997, 242, 449-454.	2.7	7
346	The Familial Hypercholesterolemia Regression Study: A Randomized Comparison of Therapeutic Reduction of Both Lowâ€Density Lipoprotein and Lipoprotein(a) Versus Lowâ€Density Lipoprotein Alone. Therapeutic Apheresis and Dialysis, 1997, 1, 187-190.	0.6	0
347	ESTROGENS AND ATHEROSCLEROSIS. Annual Review of Pharmacology and Toxicology, 1997, 37, 477-515.	4.2	145
348	Lipoprotein(a): structural implications for pathophysiology. International Journal of Clinical and Laboratory Research, 1997, 27, 14-23.	1.0	38

#	Article	IF	CITATIONS
349	Urinary excretion of apo(a) fragments in NIDDM patients. Diabetologia, 1997, 40, 1455-1460.	2.9	12
350	Small genetic effects in complex diseases: A review of regulatory sequence variants in dyslipoproteinemia and atherosclerosis. Clinical Biochemistry, 1997, 30, 183-188.	0.8	12
351	Lipoprotein(a) as a risk factor for coronary artery disease. American Journal of Cardiology, 1998, 82, 57U-66U.	0.7	150
352	Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure. Kidney International, 1998, 53, 1336-1342.	2.6	69
353	Lipoprotein(a) Apheresis in Severe Coronary Heart Disease: an Immunoadsorption Method. Artificial Organs, 1998, 22, 135-139.	1.0	15
354	Decreased urinary apolipoprotein (a) excretion in patients with impaired renal function. European Journal of Clinical Investigation, 1998, 28, 447-452.	1.7	28
355	Influence of bilateral oophorectomy upon lipid metabolism. Maturitas, 1998, 29, 147-154.	1.0	19
356	Dyslipidaemia in Adult Growth Hormone (GH) Deficiency and the Effect of GH Replacement Therapy: A Review. Trends in Endocrinology and Metabolism, 1998, 9, 200-206.	3.1	21
357	Therapeutic efficiency of lipoprotein(a) reduction by low-density lipoprotein immunoapheresis. Metabolism: Clinical and Experimental, 1998, 47, 1058-1064.	1.5	17
358	Plasma Lipoprotein(a) Levels Are High in Patients with Central Retinal Artery Occlusion. Thrombosis Research, 1998, 91, 169-175.	0.8	18
359	Evaluation of the new automated ELISA Vidas® Lp(a) assay. Clinica Chimica Acta, 1998, 272, 183-195.	0.5	0
360	Elevated Plasma Lipoprotein(a) Is Associated With Coronary Artery Disease in Patients With Chronic Stable Angina Pectoris 11Dr. Cox is supported by a Fellowship Grant from the British Heart Foundation, London Journal of the American College of Cardiology, 1998, 31, 1260-1266.	1.2	57
361	Predictive value of remnant-like particles cholesterol/high-density lipoprotein cholesterol ratio as a new indicator of coronary artery disease. American Heart Journal, 1998, 136, 226-230.	1.2	27
362	Oxidative stress in chronic renal failure. Free Radical Research, 1998, 29, 1-11.	1.5	83
363	Urinary apolipoprotein (a) excretion in patients with proteinuria. Annals of Medicine, 1998, 30, 497-502.	1.5	12
364	Male-Associated Hypertension in LDL-R Deficient Mice. Biochemical and Biophysical Research Communications, 1998, 247, 277-279.	1.0	20
365	Functional Characterization of T7 and T8 of Human Apolipoprotein (a). Biochemical and Biophysical Research Communications, 1998, 251, 356-359.	1.0	8
366	Serum lipids, lipoprotein(a) and apo(a) isoforms in patients with established coronary artery disease and their relation to disease and prognosis after coronary by-pass surgery. Atherosclerosis, 1998, 137, 175-186.	0.4	37

#	Article	IF	CITATIONS
367	Influence of lipoprotein(a) plasma concentration on neointimal growth in a monkey model of vascular injury. Atherosclerosis, 1998, 139, 137-145.	0.4	2
368	Lipoprotein(a) interactions with lipid and non-lipid risk factors in patients with early onset coronary artery disease. Atherosclerosis, 1998, 141, 333-345.	0.4	33
369	Standardization and Clinical Management of Lipoprotein(a) Measurements. Clinical Chemistry and Laboratory Medicine, 1998, 36, 5-16.	1.4	17
370	Growth Hormone Deficiency in Adulthood and the Effects of Growth Hormone Replacement: A Review. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 382-395.	1.8	772
371	Lipoprotein (a), Lipids, Aspirin, and Risk of Myocardial Infarction in the Physician's Health Study. European Journal of Cardiovascular Prevention and Rehabilitation, 1998, 5, 273-278.	3.1	2
372	Different Effects of Continuous and Intermittent Patterns of Growth Hormone Administration on Lipoprotein Levels inGrowth Hormone-Deficient Patients. Hormone Research in Paediatrics, 1998, 50, 284-291.	0.8	11
373	Serum lipoprotein (a) concentrations among Arab children: a hospital-based study in Kuwait. Annals of Tropical Paediatrics, 1998, 18, 243-248.	1.0	6
374	Low density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: No accentuation by apolipoprotein(a). Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 4544-4549.	3.3	131
375	Apo(a) Phenotypes and Lp(a) Concentrations in Renal Transplant Patients. Nephron, 1998, 80, 183-187.	0.9	6
376	International Federation of Clinical Chemistry standardization project for the measurement of lipoprotein(a). Phase I. Evaluation of the analytical performance of lipoprotein(a) assay systems and commercial calibrators. Clinical Chemistry, 1998, 44, 1629-1640.	1.5	67
377	Association of Apolipoprotein A Phenotypes and Oxidized Low-Density Lipoprotein Immune Complexes in Children. JAMA Pediatrics, 1999, 153, 57-62.	3.6	10
378	Pentanucleotide Repeat and Size Polymorphisms in the Apolipoprotein(a) Gene Are Associated with the Lipoprotein(a) Concentration in Chronic Hemodialysis Patients. Nephron, 1999, 81, 414-420.	0.9	3
379	Serum Lipoprotein (a) Levels in Chronic Renal Failure and Liver Cirrhosis Patients. Relationship with Atherosclerosis. Disease Markers, 1999, 15, 237-247.	0.6	4
380	Lipoprotein(a)-Cholesterol and Coronary Heart Disease in the Framingham Heart Study. Clinical Chemistry, 1999, 45, 1039-1046.	1.5	113
381	The relationship between plasma androgens (dehydroepiandrosterone sulfate and testosterone) and coronary arteriosclerosis in men: The lower the androgens, the higher the coronary score of arteriosclerosis. Aging Male, 1999, 2, 22-32.	0.9	6
382	Lipoprotein(a) Concentration and Apolipoprotein(a) Size. Circulation, 1999, 100, 1151-1153.	1.6	68
383	Role of Lipoprotein(a) and Apolipoprotein(a) Phenotype in Atherogenesis. Circulation, 1999, 100, 1154-1160.	1.6	261
384	International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Standardization Project for the Measurement of Lipoprotein(a). Phase 2: Selection and Properties of a Proposed Secondary Reference Material for Lipoprotein(a) Clinical Chemistry and Laboratory Medicine, 1999, 37, 949-58.	1.4	63

#	Article	IF	Citations
385	Lipid and Apolipoprotein Predictors of Atherosclerosis in Youth. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 753-761.	1.1	60
386	Lipoprotein A profiles in Arab newborns. Pediatrics International, 1999, 41, 65-69.	0.2	5
387	Plasmin activation system in restenosis: role in pathogenesis and clinical prediction?. Journal of Thrombosis and Thrombolysis, 1999, 7, 277-285.	1.0	24
388	Plasma lipoprotein (a) levels in children with minimal lesion nephrotic syndrome. Pediatric Nephrology, 1999, 13, 657-661.	0.9	9
389	Lipoprotein(a) and coronary heart disease risk. Current Cardiology Reports, 1999, 1, 105-111.	1.3	31
390	Family history of early cardiovascular disease in children with moderate to severe hypercholesterolemia: Relationship to lipoprotein (a) and low-density lipoprotein cholesterol levels. Translational Research, 1999, 133, 237-244.	2.4	11
391	Dominant Role of the C-Terminal Domain in the Binding of Apolipoprotein(a) to the Protein Core of Proteoglycans and Other Members of the Vascular Matrix. Trends in Cardiovascular Medicine, 1999, 9, 196-200.	2.3	8
392	Ionizing radiation and genetic risks. Mutation Research - Reviews in Mutation Research, 1999, 436, 21-57.	2.4	38
393	Lipoprotein(a) and coronary thrombosis and restenosis after stent placement. Journal of the American College of Cardiology, 1999, 33, 1005-1012.	1.2	26
394	Urinary excretion of apolipoprotein(a) fragments in type 1 diabetes mellitus patients. Metabolism: Clinical and Experimental, 1999, 48, 369-372.	1.5	7
395	Correlates of lipoprotein(a) levels in a biracial cohort of young girls: The NHLBI Growth and Health Study. Journal of Pediatrics, 1999, 135, 169-176.	0.9	15
396	Effects of Exercise on Lipoprotein(a). Sports Medicine, 1999, 28, 11-24.	3.1	35
397	Apolipoprotein(a) size polymorphism in young adults with ischemic stroke. Atherosclerosis, 1999, 142, 233-239.	0.4	27
398	Sequence polymorphisms in the apolipoprotein(a) gene and their association with lipoprotein(a) levels and myocardial infarction. The ECTIM Study. Atherosclerosis, 1999, 144, 323-333.	0.4	55
399	The significance of high levels of lipoprotein (a) compared with established risk factors in premature coronary artery disease: differences between men and women. Atherosclerosis, 1999, 144, 221-228.	0.4	27
400	New risk factors for coronary heart disease. American Journal of Medicine, 1999, 107, 19-21.	0.6	8
401	Apolipoprotein(a), a Link between Atherosclerosis and Tumor Angiogenesis. Biochemical and Biophysical Research Communications, 1999, 257, 714-718.	1.0	44
402	Lipoprotein(a). Current Opinion in Lipidology, 1999, 10, 225-236.	1.2	161

#	Article	IF	CITATIONS
403	An application of apo(a) isoforms for the clinical assessment of Lp(a)., 2000, 14, 53-58.		2
404	Lipoproteins and free plasma catecholamines in spinal cord injured men with different injury levels. Clinical Physiology, 2000, 20, 304-310.	0.7	48
405	Relation between lipoprotein (a) and in vitro oxidation of apolipoprotein B-containing lipoproteins. Clinical Biochemistry, 2000, 33, 303-309.	0.8	4
406	Elevation of fibrinogen and thrombin–antithrombin III complex levels of type 2 diabetes mellitus patients with retinopathy and nephropathy. Journal of Diabetes and Its Complications, 2000, 14, 121-126.	1.2	71
407	Lipoprotein Lp(a) and Atherothrombotic Disease. Archives of Medical Research, 2000, 31, 353-359.	1.5	45
408	Hemodialysis Vascular Access Thrombosis and Lipoprotein(A). Journal of Vascular Access, 2000, 1, 84-87.	0.5	1
409	Lipoprotein(a): what's in a measure?. Annals of Clinical Biochemistry, 2000, 37, 571-580.	0.8	7
410	Elevated Plasma Free Apo(a) Levels in Hemodialysis Patients. Nephron, 2000, 86, 389-390.	0.9	2
411	Production and Characterization of Monoclonal Antibodies Directed to the Kringle ν and Protease Domains of Human Apolipoprotein(a). Hybridoma, 2000, 19, 435-444.	0.9	2
412	A nine-month, placebo-controlled study of the effects of growth hormone treatment on lipoproteins and LDL size in abdominally obese men. Growth Hormone and IGF Research, 2000, 10, 118-126.	0.5	16
413	Effect of apolipoprotein e polymorphism on serum lipid, lipoproteins, and atherosclerosis in hemodialysis patients. American Journal of Kidney Diseases, 2000, 36, 826-836.	2.1	52
414	Is lipoprotein(a)-cholesterol a better predictor of vascular disease events than total lipoprotein(a) mass? A nested case control study from the West of Scotland Coronary Prevention Study. Atherosclerosis, 2000, 148, 95-100.	0.4	14
415	The evolving role of statins in the management of atherosclerosis. Journal of the American College of Cardiology, 2000, 35, 1-10.	1.2	534
416	The influence of plasma lipoprotein (a) on angiographic restenosis and coronary events in patients undergoing planned coronary balloon angioplasty Ancillary analysis of the Fluvastatin Angioplasty Restenosis (FLARE) trial. Atherosclerosis, 2001, 158, 445-454.	0.4	10
417	Effects of androgen manipulation on postprandial triglyceridaemia, low-density lipoprotein particle size and lipoprotein(a) in men. Atherosclerosis, 2001, 159, 425-432.	0.4	31
418	Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. Journal of the American College of Cardiology, 2001, 37, 434-439.	1.2	171
419	Prospective association of lipoprotein(a) concentrations and apo(a) size with coronary heart disease among men in the Multiple Risk Factor Intervention Trial. Journal of Clinical Epidemiology, 2001, 54, 51-57.	2.4	21
420	The association of serum lipoprotein(a) levels, apolipoprotein(a) size and (TTTTA)n polymorphism with coronary heart disease. Clinica Chimica Acta, 2001, 309, 45-51.	0.5	23

#	ARTICLE	IF	CITATIONS
421	DIAGNOSIS AND MANAGEMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS. Endocrinology and Metabolism Clinics of North America, 2001, 30, 545-563.	1.2	22
423	Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects. Brazilian Journal of Medical and Biological Research, 2001, 34, 177-182.	0.7	13
424	Gene targeting in hemostasis. plasminogen. Frontiers in Bioscience - Landmark, 2001, 6, d555.	3.0	6
425	Decreased longevity in Japanese men, associated with low-molecular-weight apolipoprotein(a) phenotypes. Annals of Clinical Biochemistry, 2001, 38, 120-123.	0.8	7
426	The Effects of Lipoprotein(a) on Coronary Stent Restenosis. Sunhwan'gi, 2001, 31, 476.	0.3	1
427	Title is missing!. European Journal of Cardiovascular Prevention and Rehabilitation, 2001, 8, 311-317.	1.5	22
428	Basal and Post-Methionine Serum Homocysteine and Lipoprotein Abnormalities in Patients With Chronic Liver Disease. Journal of Investigative Medicine, 2001, 49, 325-329.	0.7	12
429	Clinical implications of elevated lipoprotein(a). Current Atherosclerosis Reports, 2001, 3, 267-270.	2.0	2
430	Atherosclerosis Risk Is Higher in Continuous Ambulatory Peritoneal Dialysis Patients Than in Hemodialysis Patients. Artificial Organs, 2001, 25, 448-452.	1.0	17
431	Lipoprotein(a) Serum Levels and Vascular Diseases in an Older Caucasian Population Cohort. Journal of the American Geriatrics Society, 2001, 49, 117-125.	1.3	9
432	Mesenteric arterial thrombosis as a complication of Crohn's disease. Digestive Diseases and Sciences, 2001, 46, 2344-2346.	1.1	15
433	Serum lipoprotein(a) concentration as a cardiovascular risk factor in Kuwaiti Type 2 diabetic patients. Journal of Diabetes and Its Complications, 2001, 15, 270-276.	1.2	11
434	Serum Lipoprotein(a) Concentrations and Apolipoprotein(a) Isoforms: Association with the Severity of Clinical Presentation in Patients with Coronary Heart Disease. European Journal of Cardiovascular Prevention and Rehabilitation, 2001, 8, 311-317.	3.1	13
436	A Critical Evaluation of the Role of Lp(a) in Cardiovascular Disease: Can Lp(a) Be Useful in Risk Assessment?. Seminars in Vascular Medicine, 2002, 02, 335-344.	2.1	37
437	Lipoprotein(a) Enhances Advanced Atherosclerosis and Vascular Calcification in WHHL Transgenic Rabbits Expressing Human Apolipoprotein(a). Journal of Biological Chemistry, 2002, 277, 47486-47492.	1.6	67
438	Molecular genetics in renal medicine: what can we hope to achieve?. Nephrology Dialysis Transplantation, 2002, 17, 5-11.	0.4	21
439	Safranin staining of <i>Cyclospora cayetanensis</i> Journal of Biomedical Science, 2002, 59, 105-106.	1.2	11
440	Lipoprotein(a) Promotes Smooth Muscle Cell Proliferation and Dedifferentiation in Atherosclerotic Lesions of Human Apo(a) Transgenic Rabbits. American Journal of Pathology, 2002, 160, 227-236.	1.9	70

#	Article	IF	Citations
441	Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis, 2002, 163, 377-384.	0.4	196
442	Thyroid Disease and Lipids. Thyroid, 2002, 12, 287-293.	2.4	553
443	Long-Term Growth Hormone Replacement Therapy in Hypopituitary Adults. Drugs, 2002, 62, 2399-2412.	4.9	40
444	Growth hormone replacement therapy for adults: Into the new millennium. Growth Hormone and IGF Research, 2002, 12, 1-33.	0.5	90
445	Relation of small artery compliance and lipoprotein (a) in patients with atherosclerosis. American Journal of Hypertension, 2002, 15, 980-985.	1.0	8
446	Type of diabetes and waist–hip ratio are important determinants of serum lipoprotein (a) levels in diabetic patients. Diabetes Research and Clinical Practice, 2002, 56, 221-227.	1.1	12
447	Association of C-reactive protein with coronary heart disease risk factors in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2002, 58, 37-44.	1.1	49
448	Lipoprotein (a) in patients with aortic aneurysmal disease. Journal of Vascular Surgery, 2002, 36, 25-30.	0.6	34
449	Lipoprotein (a) in an immigrant Indian population sample in Australia. British Journal of Biomedical Science, 2002, 59, 109-111.	1.2	7
450	Relationship of renal function to homocysteine and lipoprotein(a) levels: The frequency of the combination of both risk factors in chronic renal impairment. American Journal of Kidney Diseases, 2002, 40, 916-923.	2.1	26
451	Serum lipids, lipoprotein(a) level, and apolipoprotein(a) isoforms as prognostic markers in patients with coronary heart disease. Journal of Internal Medicine, 2002, 251, 111-118.	2.7	35
452	La lipoprotéine (A). Revue Francaise Des Laboratoires, 2002, 2002, 27-29.	0.0	3
453	LDL-apheresis significantly reduces urinary apo(a) excretion. European Journal of Clinical Investigation, 2003, 27, 93-95.	1.7	17
455	Noncholesterol-Lowering Effects of Statins. Vascular and Endovascular Surgery, 2003, 37, 301-313.	0.3	22
456	Lipoprotein (a) and Apolipoprotein (a) Isoform Size in Thyroid Disease: The Quest for the Golden Fleece. Thyroid, 2003, 13, 345-346.	2.4	4
457	Singapore and coronary heart disease: a population laboratory to explore ethnic variations in the epidemiologic transition. European Heart Journal, 2003, 24, 127-129.	1.0	19
458	Relation Between Serum Lipoprotein (a) and Residual Lesion Stenosis of Coronary Artery After Myocardial Infarction Without Reperfusion Therapy. International Heart Journal, 2004, 45, 397-407.	0.6	8
459	High lipoprotein (a), diabetes, and the extent of symptomatic intracranial atherosclerosis. Neurology, 2004, 63, 27-32.	1.5	114

#	Article	IF	Citations
460	Lipoprotein (A): Better assessor of coronary heart disease risk in south Indian population. Indian Journal of Clinical Biochemistry, 2004, 19, 53-59.	0.9	22
461	Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clinical Biochemistry, 2004, 37, 333-343.	0.8	134
462	Electrophoretic measurement of lipoprotein(a) cholesterol in plasma with and without ultracentrifugation: comparison with an immunoturbidimetric lipoprotein(a) method. Clinical Biochemistry, 2004, 37, 481-488.	0.8	20
463	Clinical pharmacological aspects of growth hormone administration. Growth Hormone and IGF Research, 2004, 14, 16-44.	0.5	39
464	Review of the Derivation and Applicability of Selected Biochemical Indicators of Nutritional Status as Predictors of Chronic Disease in the Elderly. Topics in Clinical Nutrition, 2004, 19, 200-214.	0.2	1
465	Diet and Plasma Lipoproteins in Elderly With and Without Cardiovascular Disease. Topics in Clinical Nutrition, 2004, 19, 215-225.	0.2	0
466	Efficacy and safety of statins in hypercholesterolemia with emphasis on lipoproteins. Heart and Vessels, 2005, 20, 217-223.	0.5	12
467	Lipoprotein(a): Implications for clinical practice. Current Atherosclerosis Reports, 2005, 7, 327-329.	2.0	1
468	Lipoprotein(a) and Apolipoprotein(a) Isoforms. Circulation, 2005, 111, 1471-1479.	1.6	58
469	Basic Mechanisms in Intracranial Large-Artery Atherosclerosis: Advances and Challenges. Cerebrovascular Diseases, 2005, 20, 75-83.	0.8	37
470	Is Lipoprotein (a)-Apheresis Useful?. Therapeutic Apheresis and Dialysis, 2005, 9, 142-147.	0.4	14
471	Plasma lipoprotein(a) [Lp(a)] concentrations and cardiovascular events in the elderly: evidence from the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Atherosclerosis, 2005, 180, 381-388.	0.4	35
472	Lipid profile in spinal cord-injured women with different injury levels. Preventive Medicine, 2005, 40, 321-325.	1.6	16
473	Hormone Therapy and Cardiovascular Disease. Taiwanese Journal of Obstetrics and Gynecology, 2006, 45, 287-293.	0.5	3
474	Elevated Lipoprotein(a)—A Genetic Risk Factor for Premature Vascular Disease in People With and Without Standard Risk Factors: A Review. Disease-a-Month, 2006, 52, 5-50.	0.4	56
475	C-Reactive Protein and Other Emerging Blood Biomarkers to Optimize Risk Stratification of Vulnerable Patients. Journal of the American College of Cardiology, 2006, 47, C19-C31.	1.2	295
476	Distribution of Serum Lipoprotein(a) Level and its Association with Other Risk Factors in Apparently Healthy Korean. Korean Circulation Journal, 2006, 36, 150.	0.7	1
477	Lipoprotein(a), Measured With an Assay Independent of Apolipoprotein(a) Isoform Size, and Risk of Future Cardiovascular Events Among Initially Healthy Women. JAMA - Journal of the American Medical Association, 2006, 296, 1363.	3.8	183

#	Article	IF	CITATIONS
478	Effect of Peritoneal Dialysis Solution Type on Serum Lipid Levels in End-Stage Renal Disease. Renal Failure, 2007, 29, 309-313.	0.8	4
479	Combination of plant sterols and diacylglycerol oil lowers serum cholesterol and lipoprotein (a) concentrations in postmenopausal women with mild to moderate hypercholesterolemia. European E-journal of Clinical Nutrition and Metabolism, 2007, 2, 4-11.	0.4	6
480	Lp(a) enhances coronary atherosclerosis in transgenic Watanabe heritable hyperlipidemic rabbits. Atherosclerosis, 2007, 193, 269-276.	0.4	13
482	Comparison of atherosclerosis and atherosclerotic risk factors in patients receiving hemodialysis and peritoneal dialysis. Dialysis and Transplantation, 2007, 36, 205-216.	0.2	2
483	Lipoprotein (a) and the kidney. Nephrology, 1997, 3, 139-142.	0.7	0
484	Influence and interaction of diabetes and lipoprotein (a) serum levels on mortality of patients with peripheral artery disease. European Journal of Clinical Investigation, 2007, 37, 180-186.	1.7	14
485	The cardiovascular risk factor profile of Estonian school children. Acta Paediatrica, International Journal of Paediatrics, 1998, 87, 37-42.	0.7	21
486	Lipoprotein(a) as a potent risk indicator for early cardiovascular disease. Acta Paediatrica, International Journal of Paediatrics, 2002, 91, 1313-1317.	0.7	22
487	Review: Epidemiology of Lp(a) lipoprotein: its role in atherosclerotic/thrombotic disease. Clinical Genetics, 1997, 52, 281-292.	1.0	61
488	Studies on the structure and function of the apolipoprotein(a) gene. Clinical Genetics, 1994, 46, 34-41.	1.0	8
489	How often has Lp(a) evolved?. Clinical Genetics, 1996, 49, 167-174.	1.0	20
490	Lipoprotein(a) levels are increased in healthy young subjects with parental history of premature myocardial infarction. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 492-496.	1.1	15
491	The role of fibrinogen and fibrinolysis in peripheral arterial disease. Thrombosis Research, 2008, 122, 1-12.	0.8	58
492	Immunosorbent for Selective Removal of Lipoprotein (a) from Human Plasma: In Vitro Study. Artificial Organs, 1991, 15, 136-140.	1.0	35
493	Lipid Profiles of Persons With Paraplegia and Tetraplegia: Sex Differences. Journal of Spinal Cord Medicine, 2008, 31, 285-289.	0.7	8
494	Lipoprotein (a) in type 2 diabetes mellitus: Relation to LDL:HDL ratio and glycemic control. International Journal of Diabetes in Developing Countries, 2009, 29, 80.	0.3	29
495	Antiphospholipid antibodies and lipoprotein(a) in obese children. Acta Paediatrica, International Journal of Paediatrics, 2009, 98, 703-707.	0.7	0
496	Treatment of symptomatic HyperLp(a)lipoproteinemia with LDL-apheresis: a multicentre study. Atherosclerosis Supplements, 2009, 10, 89-94.	1.2	19

#	Article	lF	CITATIONS
497	Apo(a) phenotyping and long-term prognosis for coronary artery disease. Clinical Biochemistry, 2010, 43, 640-644.	0.8	7
498	CASE REPORT: Hyperlipoproteinaemia(a): which is the optimal therapy? A case report. Journal of Clinical Pharmacy and Therapeutics, 2010, 35, 613-615.	0.7	2
499	Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet. Journal of Lipid Research, 2010, 51, 3324-3330.	2.0	67
500	Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy. Journal of Lipid Research, 2010, 51, 3055-3061.	2.0	76
501	Treatment of symptomatic hyperLp(a)lipidemia with LDL-apheresis vs. usual care. Transfusion and Apheresis Science, 2010, 42, 21-26.	0.5	29
502	Effects of selective H.E.L.P. LDL-apheresis on plasma inflammatory markers concentration in severe dyslipidemia: Implication for anti-inflammatory response. Cytokine, 2011, 56, 850-854.	1.4	19
503	Lipoprotein(a) levels in coronary heart disease-susceptible and -resistant patients with familial hypercholesterolemia. Atherosclerosis, 2011, 216, 426-432.	0.4	53
504	Acidic Polysaccharide Extracts from Gastrodia Rhizomes Suppress the Atherosclerosis Risk Index through Inhibition of the Serum Cholesterol Composition in Sprague Dawley Rats Fed a High-Fat Diet. International Journal of Molecular Sciences, 2012, 13, 1620-1631.	1.8	19
505	Maternal cardiac risks in pre-eclamptic patients. Journal of Maternal-Fetal and Neonatal Medicine, 2012, 25, 912-914.	0.7	13
506	Relationship between lipoprotein(a) concentrations and intima-media thickness: a healthy population study. European Journal of Preventive Cardiology, 2012, 19, 1290-1295.	0.8	14
507	Lipoprotein (a) – An Overview. , 2012, , .		1
508	The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease. Atherosclerosis Supplements, 2013, 14, 67-70.	1.2	56
509	Lipoprotein(a) is not related to markers of insulin resistance in pregnancy. Cardiovascular Diabetology, 2013, 12, 138.	2.7	17
510	In vivo evaluation and comparison of developmental toxicity and teratogenicity of perfluoroalkyl compounds using Xenopus embryos. Chemosphere, 2013, 93, 1153-1160.	4.2	23
511	Lipoprotein apheresis for the treatment of familial hypercholesterolemia. Clinical Lipidology, 2013, 8, 573-586.	0.4	6
512	Serum lipoprotein (a) in diabetic patients with various renal function not yet on dialysis. Pakistan Journal of Medical Sciences, 2013, 29, .	0.3	12
513	Relationship between Lipoprotein(a) and Thyroid Hormones in Hypothyroid Patients. Journal of Clinical and Diagnostic Research JCDR, 2014, 8, 37-9.	0.8	12
514	Evaluation of serum lipoprotein (a) in young patients with myocardial infarction. International Journal of Medicine and Public Health, 2014, 4, 107.	0.3	3

#	Article	IF	CITATIONS
515	Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease. Journal of the American College of Cardiology, 2014, 63, 520-527.	1.2	152
516	Genetic and biochemical analyses in dyslipidemic patients undergoing LDL apheresis. Journal of Clinical Apheresis, 2014, 29, 256-265.	0.7	4
517	Flow patterns and preferred sites of atherosclerotic lesions in the human aorta $\hat{a} \in \text{``I.}$ Aortic arch. Biorheology, 2014, 51, 239-255.	1.2	11
519	Understanding the Role of Sex in Heart Valve and Major Vascular Diseases. Cardiovascular Engineering and Technology, 2015, 6, 209-219.	0.7	16
520	Effects of Long-Term Exposure to Free <i>N</i> ^{Îμ} -(Carboxymethyl)lysine on Rats Fed a High-Fat Diet. Journal of Agricultural and Food Chemistry, 2015, 63, 10995-11001.	2.4	34
521	An elevated lipoprotein(a) plasma level as a cardiovascular risk factor. Atherosclerosis Supplements, 2015, 18, 257-262.	1.2	10
522	Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. Journal of Lipid Research, 2016, 57, 1953-1975.	2.0	365
523	Combined Supplementation with Grape Pomace and Omija Fruit Ethanol Extracts Dose-Dependently Improves Body Composition, Plasma Lipid Profiles, Inflammatory Status, and Antioxidant Capacity in Overweight and Obese Subjects. Journal of Medicinal Food, 2016, 19, 170-180.	0.8	21
524	Prevalence of cardiovascular disease risk factors in Tallinn, Estonia. Medicina (Lithuania), 2017, 53, 268-276.	0.8	6
525	Semiautomatic Volumetry of Low Attenuation of Thoracic Aortic Plaques on Curved Planar Reformations Using MDCT Angiographic Data with 0.5 mm Collimation. BioMed Research International, 2018, 2018, 1-8.	0.9	1
526	Analyzing 2000 <i>in Vivo</i> Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle Delivery. ACS Nano, 2018, 12, 8341-8349.	7.3	93
527	The cholesterol-lowering effect of unripe Rubus coreanus is associated with decreased oxidized LDL and apolipoprotein B levels in subjects with borderline-high cholesterol levels: a randomized controlled trial. Lipids in Health and Disease, 2020, 19, 166.	1.2	8
528	Usefulness of Lipoprotein (a) for Predicting Outcomes After Percutaneous Coronary Intervention for Stable Angina Pectoris in Patients on Hemodialysis. American Journal of Cardiology, 2020, 136, 32-37.	0.7	0
529	Elevated Lipoprotein A in South Asians and the Associated Risk of Cardiovascular Disease: A Systematic Review. Current Problems in Cardiology, 2021, 46, 100581.	1.1	3
530	Mendelian randomization under the omnigenic architecture. Briefings in Bioinformatics, 2021, 22, .	3.2	9
531	Lipoprotein(a). Clinical approach to a unique atherogenic lipoprotein. JAMA - Journal of the American Medical Association, 1992, 267, 1109-1112.	3.8	67
532	Omega-3 Fatty Acids and Heart Disease. , 1995, , 77-137.		1
533	Genetic Mutations Affecting Human Lipoproteins, Their Receptors, and Their Enzymes., 1993, 21, 145-319.		66

#	Article	IF	CITATIONS
534	Recent Advances in Lipoprotein Metabolism and the Genetic Dyslipoproteinemias. Advances in Experimental Medicine and Biology, 1990, 285, 237-244.	0.8	5
535	Behandlung von FettstoffwechselstĶrungen: Wann? Warum?. , 1992, , 1-18.		2
536	Lipoprotein(a) Changes in Perimenopausal Years. Medical Science Symposia Series, 1994, , 125-132.	0.0	1
537	Lp(a) Lipoprotein: A Monogenic Risk Factor for Cardiovascular Disease. Developments in Cardiovascular Medicine, 1994, , 275-287.	0.1	11
538	Lp(a) Lipoprotein: An Overview., 1990,, 1-23.		7
539	Structural Properties of Apo(a): A Major Apoprotein of Human Lipoprotein(a)., 1990,, 53-74.		16
540	Genetics of the Lp(a) Lipoprotein. , 1990, , 75-85.		5
541	Effectiveness of Diet and Drugs in the Treatment of Patients with Elevated Lp(a) Levels. , 1990, , 211-220.		31
542	Cloning, expression, and characterization of human apolipoprotein(a) kringle IV37 Journal of Biological Chemistry, 1994, 269, 21820-21827.	1.6	29
543	Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. Journal of Biological Chemistry, 1991, 266, 2459-2465.	1.6	256
544	Insoluble complex formation of lipoprotein (a) with low density lipoprotein in the presence of calcium ions Journal of Biological Chemistry, 1993, 268, 4709-4715.	1.6	19
545	Rhesus Monkey Apolipoprotein(a). Journal of Biological Chemistry, 1989, 264, 5957-5965.	1.6	172
546	Defects of the LDL receptor in WHHL transgenic rabbits lead to a marked accumulation of plasma lipoprotein[a]. Journal of Lipid Research, 2000, 41, 1004-1012.	2.0	24
547	Inhibition of N-linked glycosylation results in retention of intracellular apo[a] in hepatoma cells, although nonglycosylated and immature forms of apolipoprotein[a] are competent to associate with apolipoprotein B-100 in vitro. Journal of Lipid Research, 1998, 39, 1629-1640.	2.0	22
548	Expression of apolipoprotein[a] and plasminogen mRNAs in cynomolgus monkey liver and extrahepatic tissues. Journal of Lipid Research, 1996, 37, 2029-2040.	2.0	26
549	Characterization of five mouse monoclonal antibodies to apolipoprotein[a] from human Lp[a]: evidence for weak plasminogen reactivity Journal of Lipid Research, 1989, 30, 23-37.	2.0	32
550	Partial characterization of lipoproteins containing apo[a] in human atherosclerotic lesions. Journal of Lipid Research, 1993, 34, 789-798.	2.0	46
551	Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice Journal of Lipid Research, 1994, 35, 2263-2267.	2.0	92

#	Article	IF	CITATIONS
552	In vivo fate and scavenger receptor recognition of oxidized lipoprotein[a] isoforms in rats Journal of Lipid Research, 1992, 33, 1315-1325.	2.0	34
553	Influence of short term dietary cholesterol and fat on human plasma Lp[a] and LDL levels Journal of Lipid Research, 1991, 32, 1281-1289.	2.0	61
554	Quantification of apo[a] and apoB in human atherosclerotic lesions Journal of Lipid Research, 1991, 32, 317-327.	2.0	119
556	Liprotein(a) Phenotypes in Japanese Children: A Cohort Study. Journal of Pediatric Gastroenterology and Nutrition, 1997, 24, 533-536.	0.9	4
557	The effect of endurance training on lipoprotein(a) [Lp(a)] levels in middle-aged males. Medicine and Science in Sports and Exercise, 1996, 28, 757-764.	0.2	25
558	Lipoprotein(a) in endurance athletes, power athletes, and sedentary controls. Medicine and Science in Sports and Exercise, 1996, 28, 962-966.	0.2	31
559	Acute effects of treadmill running on lipoprotein(a) levels in males and females. Medicine and Science in Sports and Exercise, 1997, 29, 436-442.	0.2	23
560	Effects of physical activity and diet on lipoprotein(a). Medicine and Science in Sports and Exercise, 1997, 29, 1429-1436.	0.2	41
561	No Association Between Plasma Lipoprotein(a) Concentrations and the Presence or Absence of Coronary Atherosclerosis in African-Americans. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 850-855.	1.1	96
562	Apo(a) Phenotypes and Lp(a) Concentrations in Offspring of Men With and Without Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 1001-1008.	1.1	24
563	Urinary Excretion of Apo(a) Fragments. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 905-911.	1.1	86
564	Genetic Variation in Factor VII Associated with Variation in Plasma Lipoprotein(a) Concentration. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 1701-1706.	1.1	15
565	Lack of Increased Coronary Atherosclerotic Risk Due to Elevated Lipoprotein(a) in Women ≥55 Years of Age. Circulation, 1996, 94, 1263-1268.	1.6	47
566	Lipoprotein(a) and Asymptomatic Carotid Artery Disease. Stroke, 1995, 26, 1582-1587.	1.0	55
567	Plasma Lipoprotein(a) Is an Independent Factor Associated With Carotid Wall Thickening in Severely but Not Moderately Hypercholesterolemic Patients. Stroke, 1996, 27, 1044-1049.	1.0	52
568	Lipoprotein (a). Heterogeneity and biological relevance Journal of Clinical Investigation, 1990, 85, 1709-1715.	3.9	548
569	Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease Journal of Clinical Investigation, 1992, 89, 1040-1046.	3.9	147
570	Hormonal regulation of serum Lp (a) levels. Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma Journal of Clinical Investigation, 1992, 89, 1166-1171.	3.9	142

#	Article	IF	CITATIONS
571	Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a) Journal of Clinical Investigation, 1993, 91, 397-401.	3.9	128
572	Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of lipoprotein(a) production Journal of Clinical Investigation, 1993, 91, 443-447.	3.9	171
573	Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level Journal of Clinical Investigation, 1994, 93, 50-55.	3.9	516
574	The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate Journal of Clinical Investigation, 1994, 93, 2758-2763.	3.9	189
575	Effect of Cardiopulmonary Bypass on Plasma Levels of Lipoprotein (a) in Hypercholesterolemic Patients International Heart Journal, 2001, 42, 563-574.	0.6	7
576	Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients Journal of the American Society of Nephrology: JASN, 1998, 9, 1277-1284.	3.0	163
577	Lack of association between plasma lipoprotein(a) concentrations and the presence or absence of coronary atherosclerosis. Acta Cardiologica, 2002, 57, 409-414.	0.3	2
578	The relationship between lipoprotein(a) and coronary artery disease, as well as its variable nature following myocardial infarction. Clinical and Investigative Medicine, 2011, 34, 14.	0.3	9
579	Atherosclerosis and the Cholesterol Theory: A Reappraisal. World Journal of Cardiovascular Diseases, 2016, 06, 391-409.	0.0	3
580	Effect of an HMG-CoA Reductase Inhibitor, CS-514, on the Total Cholesterol and Lp (a) Lipoprotein Levels in Serum. The Journal of Japan Atherosclerosis Society, 1987, 15, 1461-1464.	0.0	2
581	Concurrent Development of Hemiplegia and Angina Pectoris in a 46-year-old Man with Familial Hypercholesterolemia and Elevated Serum Lp (a) Concentrations. Journal of Atherosclerosis and Thrombosis, 1994, 1, 129-131.	0.9	1
582	Lipoprotein(a): important risk factor or passing fashion?. Medical Journal of Australia, 1993, 158, 512-514.	0.8	4
583	Family study on the relationship between serum lipoprotein (a) and ischemic heart disease. The Journal of Japan Atherosclerosis Society, 2000, 28, 1-10.	0.0	0
584	Adult Growth Hormone Deficiency. , 2002, , 105-120.		0
585	Coronary Artery Disease and Endothelial Function. , 2002, , 887-912.		0
586	A Case of Marked Hyperlipoprotein(a)emia Associated with Nephrotic Syndrome and Advanced Atherosclerosis. Journal of Atherosclerosis and Thrombosis, 2004, 11, 293-298.	0.9	5
587	Dyslipidemia: End Stage Renal Disease and Hemodialysis. The Internet Journal of Nephrology, 2009, 5, .	0.2	2
588	Physical activity, physical fitness, and cardiovascular health. , 2013, , .		1

#	Article	IF	CITATIONS
589	Lipoprotein Lp(a): Structure and Metabolism. Recent Developments in Lipid and Lipoprotein Research, 1989, , 56-63.	0.2	1
590	Disorders of Lipoprotein Metabolism. , 1990, , 75-119.		0
591	Morphometrische Analyse der Ablagerung des Lipoproteins (a) in atheromatĶsen LĤonen der Aorta und Koronararterien. , 1990, , 214-219.		0
592	Apolipoprotein B (ApoB)., 1990,, 112-183.		0
593	Distribution of Lp(a) and Lipo Z level in Healthy Adults Japanese Journal of MHTS, 1991, 18, 23-30.	0.0	0
594	Effects of the Serum Lipoprotein (a) Level on the Severity of Coronary Atherosclerosis. The Journal of Japan Atherosclerosis Society, 1991, 19, 823-828.	0.0	0
595	Relationship between Lp (a) and Arteriographic Feature of Coronary Atherosclerosis. The Journal of Japan Atherosclerosis Society, 1992, 20, 37-43.	0.0	0
596	Relationship between Lipoprotein(a) and Clinical Parameters in the Hemostatic Process. The Journal of Japan Atherosclerosis Society, 1992, 20, 645-649.	0.0	0
597	Serum Lipoprotein (a) Level and Its Distribution in Healthy Japanese Male Subjects. The Journal of Japan Atherosclerosis Society, 1992, 20, 539-543.	0.0	4
599	Serum Lipoprotein (a) in Japanese Children with Insulin-dependent-diabetes-mellitus. The Journal of Japan Atherosclerosis Society, 1993, 21, 497-501.	0.0	0
600	Genetic Variation of the Apolipoprotein(a) Gene and Coronary Heart Disease., 1993,, 139-158.		0
601	Asymptomatic Myocardial Infarction in a Diabetic Patient with Skin Sarcoid Lesions and Elevated Serum Lp(a) Concentration. The Journal of Japan Atherosclerosis Society, 1993, 21, 53-57.	0.0	0
602	Lipidapherese bei HypercholesterinÃmie. , 1993, , 63-68.		0
603	Basement of Hyperlipidemia The Japanese Journal of Nutrition and Dietetics, 1993, 51, 61-71.	0.1	0
604	Lipoprotein Metabolism. Handbook of Experimental Pharmacology, 1994, , 29-51.	0.9	0
605	Diagnostics of Lipids and Lipoproteins. , 1994, , 33-73.		0
606	Serum Lp (a) Concentration in NIDDM: Natural Fluctuations, and Effect of Glycemic Control and Niceritrol Therapy on Lp (a) Concentration. The Journal of Japan Atherosclerosis Society, 1994, 22, 209-214.	0.0	0
607	Serum Lp(a) Concentrations and Ischemic Heart Disease in Patients with NIDDM. The Journal of Japan Atherosclerosis Society, 1995, 23, 249-254.	0.0	0

#	Article	IF	CITATIONS
609	Significance of Serum Lp(a) Concentration as a Risk Factor for Diabetic Retinopathy. The Journal of Japan Atherosclerosis Society, 1996, 23, 539-544.	0.0	0
610	Plasma Lipoprotein(a) Levels Showing Age-Related Changes in Diabetic and Hypertensive Individuals Journal of Clinical Biochemistry and Nutrition, 1996, 21, 151-155.	0.6	0
611	Mechanismus of Atherosclerosis: Role of Antioxidant (Probucol), Lipid Peroxide, IDL and Oxidized LDL. The Journal of Japan Atherosclerosis Society, 1996, 23, 373-388.	0.0	0
612	Lp(a) Serum Concentration in Medical Check-up of the Brain. Relationship Between Serum Lp(a) Levels and Carotid Artery Atherosclerosis or Silent Cerebral Infarction Japanese Journal of MHTS, 1997, 24, 42-48.	0.0	0
613	$\label{lipoprotein} Lipoprotein (a), Homocysteine, and Atherogenesis. Developments in Cardiovascular Medicine, 1997, , 259-265.$	0.1	0
614	Thrombosis in the Pathogenesis of Coronary Artery Disease. Developments in Cardiovascular Medicine, 1998, , 59-86.	0.1	0
615	Mechanism by which lipoprotein(a) stimulates the proliferation of cultured arterial smooth muscle cell. The Journal of Japan Atherosclerosis Society, 1998, 25, 353-356.	0.0	0
616	Relation of serum lipoprotein (a) concentration to lesion stenosis of infarction related coronary artery in survivors of myocardial infarction. Juntendol,, Igaku, 1999, 45, 410-419.	0.1	0
617	EVALUATION OF LIPOPROTEIN (a) LEVELS IN YOUNG PATIENTS WITH MYOCARDIAL INFARCTION IN NORTH COASTAL ANDHRA REGION. Journal of Evolution of Medical and Dental Sciences, 2015, 4, 808-814.	0.1	0
618	Role of lipoprotein (a) in the development of ischemic stroke and other cardiovascular diseases. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2016, 8, 90-95.	0.2	0
619	Factors influencing plasma lipid profiles including lipoprotein (a) concentrations in renal transplant recipients. Transplant International, 1996, 9, 221-226.	0.8	13
620	Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it. EMBO Journal, 1989, 8, 4035-40.	3.5	16
621	Expressed hypervariable polymorphism of apolipoprotein (a). American Journal of Human Genetics, 1991, 49, 1063-74.	2.6	164
622	Lipoprotein(a): searching for a function. Transactions of the American Clinical and Climatological Association, 1996, 107, 125-33.	0.9	0
623	Lipoprotein(a) and its role in occlusive vascular disease. Annals of the Royal College of Surgeons of England, 1993, 75, 3-7.	0.3	33
624	Genetics of coronary artery disease: focus on genome-wide association studies. American Journal of Translational Research (discontinued), 2009, 1, 221-34.	0.0	14
625	Emerging Biomarkers of Instability. , 0, , 185-210.		1
626	The cardiovascular risk factor profile of Estonian school children. Acta Paediatrica, International Journal of Paediatrics, 1998, 87, 37-42.	0.7	12

#	Article	IF	CITATIONS
630	Targeting ABCC6 in Mesenchymal Stem Cells: Impairment of Mature Adipocyte Lipid Homeostasis. International Journal of Molecular Sciences, 2022, 23, 9218.	1.8	1
631	Premature Peripheral Atherosclerosis. Vascular, 1993, 1, 473-480.	0.5	18
632	Increase of serum lipoprotein (a), an adverse effect of growth hormone treatment. Growth Hormone and IGF Research, 2022, 67, 101503.	0.5	1
634	Elevated Lp(a) Levels Correlate with Severe and Multiple Coronary Artery Stenotic Lesions. Vascular Health and Risk Management, 0, Volume 19, 31-41.	1.0	0